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ABSTRACT

The invention is directed to methods and compositions for
inhibiting caspase-independent apoptosis. In particular,
methods and compositions for inhibiting Omi/HtrA2 activity,
as well as method for identifying other inhibitors of Omi/
HtrA2. Also disclosed are Omi/HtrA2 specific substrates and
methods for identifying other substrates ofOmi/HtrA2.
12 Claims, 10 Drawing Sheets
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METHOD AND COMPOUNDS FOR
INHIBITION OF CELL DEATH

prises the tetra peptide motif"AVPS" at its N terminus. It has
been demonstrated that the deregulated expression of Omi/
HtrA2 in the cytoplasm of mammalian cells induces apoptosis in these cells, indicating that Omi/HtrA2 could participate
in the mitochondrial apoptotic pathway.
Mature Omi/HtrA2 is released from the mitochondria into
the cytosol upon disruption of the outer mitochondrial membrane during apoptosis. Mature Omi/HtrA2 can induce apoptosis in human cells in a caspase-independent manner
through its protease activity and in a caspase-dependent manner via its ability to disrupt caspase-IAP interaction.
Since Omi/HtrA2 is present in all mammalian cells and by
its activity of disrupting the inhibition of the "apoptosis protein-caspase interaction" decreases the cell lifetime, it would
be important to discover an inhibitor of the adverse activity of
Omi/HtrA2 and homologous proteins.
Accordingly, it would be useful to identify a class ofinhibitors that inhibit Omi/HtrA2. A need also exists to determine
the peptides involved in the caspase-independent pathway of
apoptosis such as substrates ofOmi/HtrA2, as well as methods and compositions that inhibit such pathways. It would
also be useful to find ways to use these methods and compositions to prevent, reduce or ameliorate a disorder associated
with apoptosis.

RELATED CASE INFORMATION
This is Continuation-In-Part application that claims priority to U.S. Provisional Patent Application No. 60/361,902,
filed Feb. 28, 2002, and U.S. Utility patent application Ser.
No. 10/369,311, filed Feb. 20, 2003, which are incorporated
herein by their entirety.
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BACKGROUND OF THE INVENTION
The technical field of this invention relates generally to
alteration of apoptosis in a cell and modification of pathways
involved in apoptosis including the treatment of diseases that
involve apoptotic pathways. In particular, the invention pertains to a class of inhibitors that inhibit mitochondrial homeostasis, caspase-dependent, and caspase-independent apoptosis by affecting Omi/HtrA2 activity.
Apoptosis, which is also referred to as programmed cell
death, is a form of cell death characterized by membrane
blebbing and nuclear DNA fragmentation. Apoptotic cell
death is morphologically distinct from necrotic cell death and
is important in the normal development and maintenance of
multicellular organisms.
Since apoptosis functions in maintaining tissue homeostasis in a range of physiological processes such as embryonic
development, immune cell regulation and normal cellular
turnover, the dysfunction or loss of regulated apoptosis can
lead to a variety of pathological disease states. For example,
the loss of apoptosis can lead to the pathological accumulation of self-reactive lymphocytes that occurs with many
autoimmune diseases. Inappropriate loss or inhibition of apoptosis can also lead to the accumulation of virally infected
cells and of hyperproliferative cells such as neoplastic or
tumor cells. Similarly, the inappropriate activation of apoptosis can also contribute to a variety of pathological disease
states including, for example, acquired immunodeficiency
syndrome (AIDS), neurodegenerative diseases and ischemic
injury. Treatments that are specifically designed to modulate
the apoptotic pathways in these and other pathological conditions can alter the natural progression of many of these
diseases.
Although apoptosis is mediated by diverse signals and
complex interactions of cellular gene products, the results of
these interactions ultimately feed into a cell death pathway
that is evolutionarily conserved between humans and invertebrates. The pathway, itself, is a cascade of proteolytic events
analogous to that of the blood coagulation cascade.
Several gene families and products that modulate the apoptotic process have now been identified. Key to the apoptotic
program is a family of cysteine proteases termed caspases.
The human caspase family includes Ced-3, human ICE (interleukin-I-beta converting enzyme) (caspase-1), ICH-1
(caspase-2), CPP32 (caspase-3), ICEreZII(caspase-4), ICEreZII
(caspase-5), Mch2 (caspase-6), ICE-LAP3 (caspase-7),
Mch5 (caspase-8), ICE-LAP6 (caspase-9), Mch4 (caspase10), caspase 11-14, and others. Capsases can be positioned as
downstream effectors of apoptosis.
The serine protease Omi, is also involved in apoptosis. Omi
(also known as "HtrA2" and "Omi/HtrA2") was identified as
a mitochondrial direct inhibitor of apoptosis protein (IAP)
binding protein, and is released from the mitochondria upon
induction of apoptosis by apoptotic stimuli (Hegde et al.
(2002) J Biol. Chem., 277: 432-438). The mature Omi/HtrA2
protein contains a conserved !AP-binding motif that com-
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The invention is based on the discovery that the activity of
Omi/HtrA2 can be inhibited by a class of compounds referred
to as "apoptosis inhibiting compounds." The mature serine
protease Omi/HtrA2 was identified as a mitochondrial direct
baculoviral inhibitor of apoptosis protein repeat3 (BIR3)binding protein and a caspase activator (Hegde et al. (2002) J
Biol. Chem., 277: 432-438). The involvement of a mitochondrial serine protease in the apoptotic pathway emphasizes the
role of the mitochondria in cell death. Therefore, the identification and use of apoptosis. These apoptotic inhibiting compounds can be formulated into pharmaceutical compositions.
The methods and compositions of the invention can be used to
inhibit mitochondrial homeostasis, caspase-dependent, and
caspase-independent apoptosis by affecting Omi/HtrA2
activity.
Accordingly, in one aspect the invention pertains to a pharmaceutical composition for inhibiting cellular apoptosis, the
composition comprising at least one apoptosis inhibiting
compound that can modulate caspase-independent apoptosis.
The pharmaceutical composition can further comprise a
pharmaceutical acceptable excipient. In one embodiment, the
apoptosis inhibiting compound, comprise the general structure shown in FIG. la, where R 1 is selected from the group
consisting of a nitro group, a carboxy group, a hydroxide, an
aliphatic group, an aromatic group, an acyl group, an alkoxy
group, an alkylene group, an alkenylene group, an alkynylene
group, a hydroxycarbonylalkyl group, an anhydride, an
amide, an amine, and a heterocyclic aromatic group. In a
preferred embodiment, the apoptosis inhibiting compound
has the structure shown in FIG. lb. In another embodiment,
the apoptosis inhibiting compound comprises the general
structure shown in FIG. 2a where R 1 is selected from the
group consisting of a nitro group, a carboxy group, a hydroxide, an aliphatic group, an aromatic group, an acyl group, an
alkoxy group, an alkylene group, an alkenylene group, an
alkynylene group, a hydroxycarbonylalkyl group, an anhydride, an amide, an amine, and a heterocyclic aromatic group.
In a preferred embodiment, the apoptosis inhibiting compound has the structure shown in FIG. 2b. In yet another
embodiment, the apoptosis inhibiting compound comprises

US 7,713,981 B2
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the general structure shown in FIG. 3a, where R 1 is selected
from the group consisting of a nitro group, a carboxy group,
a hydroxide, an aliphatic group, an aromatic group, an acyl
group, an alkoxy group, an alkylene group, an alkenylene
group, an alkynylene group, a hydroxycarbonylalkyl group,
an anhydride, an amide, an amine, and a heterocyclic aromatic group. In a preferred embodiment, the apoptosis inhibiting compound has the structure shown in FIG. 3b. In yet
another embodiment, the apoptosis inhibiting compound
comprises the general structure shown in FIG. 4a, where R 1 is
selected from the group consisting of a nitro group, a carboxy
group, a hydroxide, an aliphatic group, an aromatic group, an
acyl group, an alkoxy group, an alkylene group, an alkenylene
group, an alkynylene group, a hydroxycarbonylalkyl group,
an anhydride, an amide, an amine, and a heterocyclic aromatic group. In a preferred embodiment, the apoptosis inhibiting compound has the structure shown in FIG. 4b.
The pharmaceutical composition may also comprise a mixture of apoptosis inhibiting compounds as long as the apoptosis inhibiting compounds in the mixture can modulate
caspase-independent apoptosis. For example, the composition may have any combinations of the compounds shown in
FIGS. 1-4.
In another aspect, the invention pertains to a method for
inhibiting caspase-independent apoptosis in a cell by contacting a cell having Omi/HtrA2 activity with at least one apoptosis inhibiting compound, such that the apoptosis inhibiting
compound interacts with Omi/HtrA2 to inhibit the activity of
Omi/HtrA2, wherein the inhibition of Omi/HtrA2 activity
reduces apoptosis in the cell; and monitoring the inhibition of
apoptosis. The inhibiting compound can selected from the
group consisting of the structure shown in FIG. la, FIG. 2a,
FIG. 3a and FIG. 4a. Preferably, the apoptosis inhibiting
compound has the structure shown in FIG. lb, FIG. 2b, FIG.
3b, and FIG. 4b.
In yet another aspect, the invention pertains to a method of
inhibiting Omi/HtrA2 activity, comprising contacting a cell
having Omi/HtrA2 activity with an apoptosis inhibiting compound; and monitoring the inhibition of Omi/HtrA2 activity.
The cell to be contacted can either be an in vitro cell or an in
vivo cell. The apoptosis inhibiting compound can be anyone
of the aforementioned inhibitors. The step of monitoring
Omi/HtrA2 activity can be by monitoring a change in fluorescene of an Omi/HtrA2 substrate coupled to a fluorescent
marker, or by monitoring the inhibition of Omi/HtrA2 activity further comprises monitoring apoptosis of the cell.
In yet another aspect, the invention pertains to a method for
modifying a disorder associated with caspase-independent
apoptosis comprising administering a therapeutically effective amount of a composition comprising at least one apoptosis inhibiting compound such that the apoptosis inhibiting
compound interacts with Omi/HtrA2 to inhibit the activity of
Omi/HtrA2, wherein the inhibition of Omi/HtrA2 activity
reduces apoptosis in the cell; and monitoring the amelioration
of the disorder by measuring the change in caspase-independent apoptosis. The disorder can be selected from the group
consisting of kidney failure, heart failure, heart attack, stroke,
neurodegenerative disease, cancers and tumors. In a preferred
embodiment, the disorder is kidney failure.
In yet another aspect, the invention pertains to a method of
preventing tubular cell death, comprising administering an
apoptosis inhibiting compound, wherein the apoptosis inhibiting compound interacts with Omi/HtrA2 such that the apoptosis inhibiting compound interacts with Omi/HtrA2 to
inhibit the activity of Omi/HtrA2, wherein the inhibition of
Omi/HtrA2 activity prevents tubular cell death; and monitoring the prevention of tubular cell death. The tubular cell death

can be associated with the proximal tubules of the kidney, and
may cause renal apoptosis and/or renal ischeamia.
In yet another aspect, the invention pertains to a method for
identifying a substrate associated with caspase-independent
apoptosis, comprising contacting a cell extract with recombinant Omi/HtrA2, wherein the recombinant Omi/HtrA2 has
proteolytic activity. The results from the contacted cell extract
can be compared with the results of the with a control sample
that has not been incubated with recombinant Omi/HtrA2. A
substrate associated with caspase-independent apoptosis can
be identified by monitoring a change in the electophoretic
mobility of a protein in the cell extract incubated with recombinant Omi/HtrA2, such that a change in electophoretic
mobility of the protein indicates that the protein is a substrate
ofOmi/HtrA2. The change in electophoretic mobility can be
the disappearance of a protein in the cell extract incubated
with recombinant Omi/HtrA2. In one embodiment, the protein associated with caspase-independent apoptosis is
obtained from a kidney cell extract. Preferably, the protein
associated with caspase-independent apoptosis is a substrate
for Omi/HtrA2. In one embodiment, the substrate associated
with caspase-independent apoptosis is 14-3-3. In another
embodiment, the substrate associated with caspase-independent apoptosis is Annexin V.
In yet another embodiment, the invention pertains to a
method for identifying a compound that inhibits caspaseindependent apoptosis, comprising contacting the candidate
compound with a substrate coupled to a fluorescent marker in
the presence of recombinant Omi/HtrA2, wherein the recombinant Omi/HtrA2 has proteolytic activity against the substrate, and monitoring the change in fluorescence, whereby a
candidate compound is identified as being an inhibitor of
caspase-independent apoptosis if the candidate compound
inhibits or blocks the proteolytic activity of recombinant
Omi/HtrA2. The substrate can be a specific Omi/HtrA2 substrate selected from the group consisting of 14-3-3 and
annexin V. Alternatively, the substrate can be a general substrate such as casein. The fluorescent marker can be selected
from the group consisting of fluorescein isothiocyanate
(FITC), cyanine dye-5 (CY5), cyanine dye-3 (Cy3), cyanine
dye-7 (Cy7), allophycocyanin (APC), tetramethyl rhodamine
isothiocyanate (TRITC), and phycoerythrin (PE). Preferably,
the fluorescent marker is FITC. The recombinant Omi/HtrA2
is MBP-Omi 134 _458
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FIG. la is the general structure of an apoptosis inhibiting
compound, and FIG. lb is the specific structure ofUcf 101;
FIG. 2a is the general structure of an apoptosis inhibiting
compound, and FIG. 2b is the specific structure ofUcf 102;
FIG. 3a is the general structure of an apoptosis inhibiting
compound, and FIG. 3b is the specific structure ofUcf 103;
FIG. 4a is the general structure of an apoptosis inhibiting
compound, and FIG. 4b is the specific structure ofUcf 104;
FIG. 5 is a schematic drawing showing caspase-dependent
and caspase-independent pathways involving Omi/HtrA2;
FIG. 6 is a schematic drawing showing the functional
domains ofOmi/HtrA2;
FIG. 7 is a graph showing the inhibition of MBP-Omi
(134-458) in the presence of ucf-101 and several other ucf
analogs;
FIG. 8 is a photograph of an SDS-PAGE gel showing the in
vitro proteolytic activity ofMBP-Omi (134-458) in the presence of different concentrations of ucf 101;
FIG. 9 is a graph showing the inhibition of proteolytic
activity ofMBP-Omi (134-458) and MBP-L56 (14-480);

US 7,713,981 B2
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FIG. 10 is a bar graph showing the inhibition of Omiinduced caspase independent cell death by ucf-101 ;
FIG. lla is a photograph of Western blot showing that the
protein levels of Omi/HtrA2 increases in MPT cells induced
with various cisplatin and antimycin apoptotic stimuli, while
FIG. llb shows the increase in the presence of hydrogen
peroxide;
FIG. 12 is a bar graph showing that ucf-101 blocks cisplatin-induced apoptosis in MPT cells;
FIG. 13 is a schematic drawing showing the different Omi
constructs;
FIG. 14 is a photograph of an SDS-PAGE gel showing the
expression and processing of the various Omi constructs; and
FIG. 15 is a bar graph showing the results of an apoptosis
assay using the various Omi constructs;

as "FLICE;" "MACH;" "Mch5"), Caspase-9 (also known as
"ICE-LAP6;" "Mch6"), Caspase-10 (also known as "Mch4,"
"FLICE-2").
The phrase "caspase-dependent apoptosis" as used herein
refers to an apoptosis pathway that involves caspases. In a
caspase-dependent apoptosis pathway, mature Omi/HtrA2
comprising the tetrapeptide motif'AVPS" which binds to
x-chromosome linked InhibitorofApoptosis Protein (XIAP),
and causes caspase activation, which results in apoptosis.
The phrase "caspase-independent apoptosis" as used
herein refers to apoptosis pathway that does not involves
caspases. Instead, Omi/HtrA2 behaves like a serine protease
exhibiting proteolytic activity. When Omi/HtrA2 functions as
a protease, it proteolytically cleaves specific protein substrates leading to apoptosis.
The term "apoptosis inhibiting compound" as used herein
refers to an agent that can reduce apoptosis by a detectable
amount by acting on a pathway involved in apoptosis. The
agent can act by inhibiting or blocking a particular step in the
apoptotic pathway, for example by blocking or inhibiting the
activity of protein involved in the pathway, such as inhibiting
the activity of Omi/HtrA2. The apoptotic pathway includes
both caspase-dependent apoptosis, as well as caspase-independent apoptosis. In a preferred embodiment, the apoptosis
inhibiting compound acts on the caspase-independent apoptosis pathway to reduce or inhibit apoptosis by a detectable
amount. Examples of apoptosis inhibiting compounds,
include, but are not limited to those structures shown in FIG.
la, FIG. 2a, FIG. 3a, and FIG. 4a. Preferred apoptosis inhibiting compounds are referred to as "Ucf-101" (shown in FIG.
lb), "Ucf-102" (shown in FIG. 2b), "Ucf-103" (shown in
FIG. 3b) and "Ucf 104" (shown in FIG. 4b). A particularly
preferable apoptosis inhibiting compound is Ucf 101. Also
within the scope of the invention are the use of combinations
and mixtures of apoptosis inhibiting compounds, for
example, a mixture comprising Ucf-101 and Ucf-102; Ucf101, Ucf-102, and Ucf-103; or Ucf-101, Ucf-102, Ucf-103
and Ucf 104, or any combinations thereof.
The term "inhibit" or "inhibiting" as used herein refers to a
measurable reduction of apoptotic activity. Preferably a
reduction of activity of at least about 20%. More preferably
the reduction of activity is about 30%, 40%, 50%, 60%, 80%,
90% and even more preferably, about 100%.
The term "modulate" or "modify" are used interchangeably herein and refer to an alleviation of at least one target
protein or gene involved in the caspase-independent pathway
for apoptosis. Such that apoptosis is inhibited or reduced. A
target protein can be for example, Omi/Htr2A. Modification
of the Omi/Htr2A may occur when an apoptosis inhibiting
compound interacts with Omi/Htr2A an alters the functional
activity of Omi/Htr2A. A modification in apoptosis can be
assessed by monitoring cell blebbing DNA fragmentation,
and the like.
The phrase "a disorder associated with Omi/Htr2A
activty" or "a disease associated with Omi/Htr2A activity" as
used herein refers to any disease state associated with the
expression of Omi/Htr2A. Examples include but are not limited to kidney failure, ischemia-reperfusion injury, heart failure, neurodegeneration disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease and
amytrophic lateral sclerosis; inflammation; osteoarthritis;
human immunodeficiency virus); bacterial infection, cell
proliferative disorders, cancers, and diabetes.
The term "subject" as used herein refers to any living
organism in which an immune response is elicited. The term
subject includes, but is not limited to, humans, nonhuman
primates such as chimpanzees and other apes and monkey
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DETAILED DESCRIPTION
The practice of the present invention employs, unless otherwise indicated, conventional methods of virology, microbiology, molecular biology and recombinant DNA techniques
within the skill of the art. Such techniques are explained fully
in the literature. (See, e.g., Sambrook, et al. Molecular Cloning: A Laboratory Manual (Current Edition); DNA Cloning:
A Practical Approach, Vol. I & II (D. Glover, ed.); Oligonucleotide Synthesis (N. Gait, ed., Current Edition); Nucleic
Acid Hybridization (B. Hames & S. Higgins, eds., Current
Edition); Transcription and Translation (B. Hames & S. Higgins, eds., Current Edition); CRC Handbook of Parvoviruses,
Vol. I & II (P. Tijessen, ed.); Fundamental Virology, 2nd
Edition, Vol. I & II (B. N. Fields and D. M. Knipe, eds.))
So that the invention is more clearly understood, the following terms are defined:
The term "apoptosis" as used herein refers to the art recognized use of the term for an active process of programmed
cell death characterized by morphological changes in the cell.
Apoptosis is characterized by membrane blebbing and
nuclear DNA fragmentation. Apoptosis can occur via two
pathways, the caspase-dependent pathway, where involves
caspases where Omi/HtrA2 interacts with an inhibitor of
apoptosis protein (IAP) and activates the caspase pathway.
Alternatively, apoptosis can occur via the caspase-independent pathway, where Omi/HtrA2 acts as a serine protease and
does not involve caspases.
The phrase "inhibitor of apoptosis protein (IAP)" as used
herein refers to the art recognized use of the phrase for a
protein that contains at least one copy ofBaculovirus IAP of
a repeat (BIR) domain and suppresses apoptosis when overexpressed and is known to bind and inhibit caspases.
The term "zymogen" as used herein refers to the inactive
proform of an enzyme e.g. a caspase, which is typically
activated by proteolysis.
The term "caspase" as used herein refers to a cysteine
protease that specifically cleaves proteins after Asp residues.
Caspases are initially expressed as zymogens, in which a
large subunit is N-terminal to a small subunit. Caspases are
generally activated by cleavage at internal Asp residues.
Caspases are found in a myriad of organisms, including
human, mouse, insect (e.g., Drosophila), and other invertebrates (e.g., C. elegans). The caspases include, but are not
limited to, Caspase-1 (also known as "ICE"), Caspase-2 (also
known as "ICH-1"), Caspase-3 (also known as "CPP32,"
"Yama," "apopain"), Caspase-4 (also known as "ICErezIJ';
"TX," "ICH-2"), Caspase-5 (also known as "ICErezIJ'; "TY"),
Caspase-6 (also known as "Mch2"), Caspase-7 (also known
as "Mch3," "ICE-LAP3" "CMH-1"), Caspase-8 (also known
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species; farm animals such as cattle, sheep, pigs, goats and
horses; domestic mammals such as dogs and cats; laboratory
animals including rodents such as mice, rats and guinea pigs,
and the like. The term does not denote a particular age or sex.
Thus, adult and newborn subjects, as well as fetuses, whether
male or female, are intended to be covered.
The invention is described in more detail in the following
sections:

94, 10183-10188; Vucic et al. (1998)Mol. Cell. Biol. 18,
3300-3309; and Srinivasula et al. (2002) Cur. Biol. 12, 125130).
Omi/HtrA2 is present in the mitochondria and is released
to the cytoplasm upon induction ofapoptosis. In this capacity,
Omi/HtrA2 is unique both in its structure as well as its function. In the cytoplasm, Omi/HtrA2 can induce apoptosis
through a caspase-dependent as well as in a caspase-independent pathway.
Omi/HtrA2 belongs to a family of mammalian serine proteases; its proteolytic activity is necessary for auto-processing to expose the AVPS motif. Furthermore, Omi/HtrA2 can
also induce apoptosis in a manner that does not depend on the
AVPS motif but depends entirely on its ability to function as
a protease (Suzuki, et al. (200l)Mol. Cell., 8, 613-21; Hegde,
et al. (2002) J. Biol Chem, 277, 432-8; Martins, et al. (2002)
J. Biol. Chem., 277, 439-44; and Verhagen, et al. (2002) J.
Biol. Chem., 277, 445-54). Thus suggests specific substrates
for Omi/HtrA2 may exist and their cleavage (whether this
leads to activation of a precursor or a destruction of a protein)
may be a part of the apoptotic process. One other member of
family of proteases is L56/HtrA1, is a serine protease that is
overexpressed in osteoathritic cartilage (Hu, et al. (1998) J.
Biol. Chem., 273, 34406-12) and is also repressed in fibroblasts following SV40 infection (Zumbrunn, et al. (1996)
FEBSLett., 398, 187-92). ThesimilaritybetweenOmi/HtrA2
and other proteins is restricted to their carboxyl terminus
which includes the proteolytic domain and PDZ motif while
the amino termini of the two proteins are different (Faccio, et
al. (2000) J. Biol. Chem., 275, 2581-8). Unlike Omi/HtrA2,
which remains intracellular, L56/HtrA 1 is secreted (Faccio,
et al. (2000) supra; and Hu, et al. (1998) J. Biol. Chem., 273,
34406-12).
When Omi/HtrA2 induces apoptosis in a caspase-independent pathway, it does so by relying entirely on its ability to
function as a serine protease (Suzuki et al. (2001) Mal. Cell.
8, 613-621; Hegde et al. (2002) J. Biol. Chem. 277, 432-438;
and Verhagen et al. (2002) J. Biol. Chem. 277, 445-454).
Neitherthe mechanism nor the significance of this function of
Omi/HtrA2 is clearly understood.
Structurally, Omi/HtrA2 is a 458 amino acid polypeptide
that was originally isolated as an interactor of Mxi2 kinase
(Faccio, et al. (2000) J. Biol. Chem., 275, 2581-8). It was
subsequently identified as an interactor of presenilin, a protein found mutated in some cases of Alzheimer's disease
(Gray, et al. (2000)EurJ Biochem, 267, 5699-710). There are
three distinct domains in the Omi/HtrA2 protein: a catalytic
domain, a PDZ domain and an amino terminal domain (see
FIG. 6). The amino-terminal domain carries a mitochondrial
targeting sequence (MTS) and three copies of a motif
PRAAXXTXX (SEQ ID No:l), where Xis any amino acid.
The function of this motif is not yet known. This amino
terminal domain of Omi (aa 1-133) is cleaved through an
intra-molecular reaction to create the mature Omi/HtrA2 protein. The mature Omi/HtrA2 has a new exposed amino terminal sequence (AVPS) that is similar to the sequence present
in other known inhibitors of apoptosis (IAP)-binding proteins
(See Table 1). This family of proteins includes the only other
known IAP binding protein Smac/DIABLO (Du, et al. (2000)
Cell, 102, 33-42; and Verhagen, et al. Cell, 102, 43-53), as
well as three Drosophila proteins Reaper (Vucic, et al. (1997)
Proc. Natl. Acad. Sci. USA, 94, 10183-8; and Vucic, et al.
(1997) Mal Cell Biol, 17, 667-76), Hid (Vucic, et al. (1998)
Mal Cell Biol, 18, 3300-9) and Grim (Chen, et al. (1996)
Genes Dev, 10, 1773-82). Besides the presence of the IAPbinding motif, no other similarity is found between these
proteins.
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10
I. Apoptosis and Omi/HtrA2
In one aspect, the invention pertains to reducing, inhibiting,
preventing or altering apoptosis, particularly caspase-independent apoptosis. Apoptosis or programmed cell death was
originally described by Kerr et al., in 1972 (Kerr, et al. (1972)
Br J Cancer, 26, 239-57), as a new cell-autonomous mecha- 15
nism of death aimed at removing damaged, mutated or aged
cells. Mitochondria, are directly linked to the process of apoptosis to the extent that they are now termed "killer
organelles" (Ravagnan, et al. (2002) J Cell Physiol, 192,
131-7). Mitochondria contain several proteins in their inter- 20
membrane space which are released in response to pro-apoptotic stimuli. These diverse proteins include cytochrome c,
AIF, Smac/Diablo, endonuclease G and Omi/HtrA2 (See e.g.,
Van Loo, et al. (2002) Cell Death Differ, 9, 1031-42). Each of
these proteins has a distinct function but they are all pro- 25
apoptotic and, invariably, their release from the mitochondria
induces cell death. Omi/HtrA2, the most recent member of
this group, was originally isolated and characterized as a new
members of the stress-signaling pathway (Faccio, et al.
(2000) J. Biol. Chem., 275, 2581-8). Omi/HtrA2 has high 30
sequence homology to bacterial HtrAs, proteins that act as
chaperones at normal temperatures and as proteases at
elevated temperatures to remove damaged or denatured proteins (Pallen, et al. (1997) Mal. Microbial., 26, 209-21).
35
Omi/HtrA2 is a human serine protease that has extensive
homology to bacterial high temperature requirement A
(HtrA) proteins (Faceio et al. (2000) J Biol Chem. 275, 25812588; and Gray et al. (2000) Eur., J. Biochem. 267, 56995710). Bacterial HtrAs have a dual function, acting as chap- 40
erones at normal temperatures and as proteases at elevated
temperatures and removing damaged or denatured proteins,
allowing the recovery and survival of bacteria following
stress (Pallen et al. (1997) Mal. Microbial. 26, 209-221; and
Spiess et al. (1999) Cell 97, 339-347).
45
Mammalian Omi/HtrA is a ubiquitous protein, although
tissue-specific alternatively spliced forms have been reported
(Gray et al. (2000) Eur., J. Biochem. 267, 5699-5710; and
Faccio et al. (2000) Genomics 68, 343-347). Recent studies
described Omi as a mitochondrial protein that upon induction 50
of apoptosis is released to the cytoplasm where it binds XLAP
(X chromosome-linked inhibitor of apoptosis protein) resulting in caspase-9 activation (Suzuki et al. (2001) Mal. Cell. 8,
613-621; Hegde et al. (2002) J. Biol. Chem. 277, 432-438;
Martins et al. (2002) J Biol. Chem. 277, 439-444; Verhagen et 55
al. (2002) J. Biol. Chem. 277, 445-454; and van Loo et al.
(2002) Cell Death Differ. 9, 20-26). In this regard, Omi
resembles Smac/DIABLO, which also binds IAPs and as a
result activates caspase-9 (Flu et al. (2000) Cell I 02, 33-42;
and Verhagen et al. (2000) Cell 102, 43-53).
60
Omi/HtrA2 protein is synthesized as a precursor that is
processed in the mitochondria to produce the mature protein.
This processing exposes an internal tetrapeptide motif,
AVPS, at the amino terminus. A similar motif is found in all
!AP-binding proteins, including the Drosophila Grim, 65
Reaper, Hid, and Sickle (Chen et al. (1996) Genes Dev. 10,
1773-1782; Vucic et al. (1997) Proc. Nail. Acad. Sci. US. A.
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TABLE 1
Comparison of known IAP-binding motifs found in two marumalian
(Omi/HtrA2 and Smac/DIABLO) and tbree Drosophila proteins
Omi/HtrA2
Smac/Diablo
Reaper
Hid
Grim

AVPSPPPA
AVPIAQKS
AVAFYIPD
AVPFYLPE
AIAYFIPD
10

Omi/HtrA2 mRNA is expressed ubiquitously, and the gene
is localized on human chromosome 2p12. Omi/HtrA2 interacts with Mxi2, an alternatively spliced form of the p38
stress-activated kinase and, when made in a heterologous
system, shows proteolytic activity against a non-specific su~
strate ~-casein. The proteolytic activity of Omi/HtrA2 1s
markedly up-regulated in the mouse kidney following
ischemia/reperfusion. (See Examples)
Therefore, Omi/HtrA2 promotes cell death via two different pathways: one that relies on IAP binding and inhibition
and involves caspase activation, and the second which
depends on its proteolytic activity and is caspase-independent. (See FIG. 5)
Alternative forms of Omi/HtrA2 are also within the scope
of the invention and include alternative splice forms and their
encoded polypeptides. In one embodiment, the alternatively
spliced form of Omi/HtrA2 is D-Omi that is expressed predominantly in the kidney (See Examples). To identify the
origin of this alternatively spliced form, the genomic locus of
Omi/HtrA2 was characterized and found to be present on the
human chromosome 2p 12. Omi gene consists of eight exons,
two of them are absent in the kidney specific D-Omi. D-Omi
is not able to bind to the Mxi2 protein due to its modified PDZ
domain. Furthermore, D-Omi has no detectable proteolytic
activity when tested against ~-casein, a generic substrate.
D-Omi lacks the amino acid sequence encoded by two
exons and is structurally quite distinct from Omi/HtrA2. It
has a modified PDZ domain and shows no detectable proteolytic activity. The data shown in the Examples section
suggest that D-Omi may have a unique function, different
from Omi/HtrA2, in the tissues where it is expressed. D-Omi
may also function in apoptosis and it may have role in modulating cellular events following tubular cell injury, such as
renal tubule cell injury.
Variants of the Omi/HtrA2 nucleic acid molecules and the
proteins they encode are also within the scope of the invention these include natural variants (e.g., polymorphisms,
spli~e variants or mutants) and those produced by genetic
engineering (e.g., substitutions, deletions or addition ofresidues ). Many methods for generating mutants have been
developed (see generally, Ausubel et al., supra). Preferred
methods include alanine scanning mutagenesis and PCR generation of mutants using an oligonucleotide containing the
desired mutation to amplify mutant nucleic acid molecules.
Variants generally have at least 70% or 75% nucleotide identity to the native sequence, preferably at least 80%-85%, and
most preferably at least 90%, 92%, 93%, 94%, 95%, 96%,
97%, 98% or 99% nucleotide identity.
Further, a nucleotide variant will typically be sufficiently
similar in sequence to hybridize to the reference sequence
under moderate or stringent hybridization conditions. For
nucleic acid molecules over about 500 bp, stringent conditions include a solution comprising about 1 MNa+ at25 to 30°
C. below the Tm; e.g., 5xSSPE, 0.5% SDS, at 65 C.; see
Ausubel et al., Current Protocols in Molecular Biology,
Greene Publishing, 1995; Sambrook et al., Molecular Clan-
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ing: A Laboratory Manual, Cold Spring Harbor Press, 1989).
Typically, homologous polynucleotide sequences can be confirmed by hybridization under stringent conditions, as is
known in the art. For example, using the following wash
conditions: 2xSSC (0.3 M NaCl, 0.03 M sodium citrate, pH
7.0), 0.1 % SDS, room temperature twice, 30 minutes each;
then 2.times.SSC, 0.1 % SDS, 50° C. once, 30 minutes; then
2xSSC, room temperature twice, 10 minutes each, homologous sequences can be identified which contain at most about
25-30% basepair mismatches. More preferably, homologous
nucleic acid strands contain 15-25% basepair mismatches,
even more preferably 5-15% basepair mismatches.
The term "homology" or "identity" or "homologous" as
used herein refers to the percentage oflikeness between molecules. To determine the homology or percent identity of two
amino acid sequences or of two nucleic acid sequences, the
sequences are aligned for optimal comparison purposes (e.g.,
gaps can be introduced in one or both of a first and a second
amino acid or nucleic acid sequence for optimal alignment
and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a
reference sequence aligned for comparison purposes is at
least 30%, preferably at least 40%, more preferably at least
50%, even more preferably at least 60%, and even more
preferably at least 70%, 80%, or 90% of the length of the
reference sequence. The amino acid residues or nucleotides at
corresponding amino acid positions or nucleotide positions
are then compared. When a position in the first sequence is
occupied by the same amino acid residue or nucleotide as the
corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid
or nucleic acid "identify" is equivalent to amino acid or
nucleic acid "homology"). The percent identify between the
two sequences is a function of the number of identical positions shared by the sequences, taking into account the number
of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
The comparison of sequences and determination of percent
identify between two sequences can be accomplished using a
mathematical algorithm. For example, the percent identity
between two amino acid sequences can be determined using
the Needleman and Wunsch (1970) J Mal. Biol. (48):444453) algorithm which has been incorporated into the GAP
program in the GCG software package (available at http://
www.gcg.com), using either a Blossom 62 matrix or a
PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4
anda length weight of 1, 2, 3, 4, 5, and 6. In another example,
the percent identify between two nucleotide sequences is
determined using the GAP program in the GCG software
package (available at http://www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80
and a length weight of 1, 2, 3, 4, 5, or 6. In yet another
example, the percent identify between two amino acid or
nucleotide sequences is determined using the algorithm ofE.
Meyers and W. Miller (CABIOS, 4:11-17(1989)) which has
been incorporated into the ALIGN program (version 2.0),
using a PAMl 20 weight residue table, a gap length penalty of
12 and a gap penalty.
III. Omi/HtrA2 and Tubular Cell Death
In one aspect, the invention pertains to inhibiting tubular
cell death by modifying apoptosis, preferably by modifying
caspase-independent apoptosis. In a particularly preferred
embodiment, the methods and compositions of the invention
can be used for acute renal failure (ARF).
ARF is a serious medical problem that occurs in 5% of all
hospitalized patients. The prognosis of ARF is poor, has
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remained unchanged over the past three decades, and carries
a high mortality rate of about 50%. AlthoughARF is the result
of many causes, the most common cause is injury to the renal
tubular epithelial cells (RTEC).
The invention relates to the role of Omi/HtrA2 in the apoptotic cell death that occurs in RTEC, as well as the molecular
events that follow its activation leading to apoptosis. By
blocking the activity of Omi/HtrA2 using a specific inhibitor,
a new approach to protect and maintain cell viability is available.
The cell death that follows renal injury is both apoptotic as
well as necrotic (Lieberthal, et al. (1998) Semin Nephrol, 18,
505-18). The relative contribution of these two forms of cell
death to tubular necrosis is not yet known. It depends both on
the nature as well as severity of insult. Severe injury (e.g.
ishcedmic injury) usually triggers necrosis whereas milder
insults to the kidney cause apoptotic death of the RTEC.
Necrosis is difficult to prevent but apoptosis can potentially
be modulated to maintain cell viability. Therefore, identifying the different components of the apoptotic pathway, especially the ones that play a major role in kidney, provides new
information on the apoptotic process. These new components
can also provide specific and novel targets for intervention to
help patients with acute renal failure.
Most of the previous studies on tubular apoptosis have
focused on the role of caspases and their activation and have
utilized caspase-specific inhibitors in an attempt to inhibit
apoptosis and protect tubular cells from ischemic as well as
toxic insults (See e.g., Ueda, et al. (2000) Am J Med, 108,
403-15; and Ueda, et al. (2000) Nephrol Dial Transplant, 15,
318-23). Omi/HtrA2 is a pro-apoptotic protease and is the
only protein identified thus far that is able to cause apoptosis
in a caspase-dependent as well as caspase-independent manner. The caspase-independent pathway is not yet clearly
understood but relies on the ability of Omi/HtrA2 to function
as a serine protease.
Table 2 lists known inducers of apoptosis of tubular cells in
acute renal failure. Caspases have been shown to be activated
both by ischemic as well as cytotoxic insults to cultured
RTECs (Lau, et al. (1999) Kidney Int, 56, 1295-8; Hortelano,
et al. (2000) J Am Soc Nephrol, 11, 2315-23; van de Water, et
al. (2000)J. Biol Chem, 275, 25805-13. 2000; and Kaushal, et
al. (2001) Kidney Int, 60, 1726-36) as well as kidney cells in
vivo (Daemen; et al. (2001) Transplantation, 71, 778-84; Shi,
et al. (2000) Am J Physiol, 279, F509-l 7; Sano, et al. (2000)
Kidney Int, 57, 1560-70; and Bonventre, (1998) Kidney &
Blood Pressure Research, 21, 226-9). Furthermore, inhibition
of caspases ameliorates ischemia-reperfusion injury in the
kidney (Daemen, et al. (1999) J Clin Invest, 104, 541-9).

The protein level of Omi/HtrA2 increased dramatically 24
hours after ischemia/reperfusion as well as in MPT cells
treated with antimycin or cisplatin (inducers of apoptosis).
The amount of Omi/HtrA2 protein increases dramatically
after ischemic or chemical injury in the mouse kidneys or
MPT cells. Furthermore, inhibiting the proteolytic activity of
Omi/HtrA2 using the ucf-101 inhibitor protects MPT cells
from cisplatin-induced apoptosis.
Though not bound by any theory, Omi/HtrA2 may exert its
caspase-independent effect by proteolytic cleavage of potential substrates leading to the destruction and removal of the
substrates as part of this process. Alternatively, Omi/HtrA2,
through specific proteolytic cleavage, might activate precursor proteins that are part of the caspase-independent apoptotic
process.
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TABLE2
Potential causes of apoptosis of tubular cells in acute renal failure
The default pathway
of apoptosis
Renal tubular
cell injury
Receptor-ligand
interactions

Grow factor deficiency: Rapamycin
Loss of cell-matrix adhesion, Loss of cell-cell
adhesion
Ischemia!hypoxia: Oxidant stress
Pharmacologic agents: Cisplatin,
Aminoglycosides, Amphotericin B
Fas-FasL: TNF-a-TNF Receptor type 1,
Angiotensin 11-angiotensin II receptor type 2
(ATR2)

Omi/HtrA2 plays a role in the apoptosis that occurs in
RTECs following renal injury. The data in the Examples
section shows that Omi/HtrA2 is predominantly expressed in
the proximal tubular cells in both human and mouse kidneys.
This area of the kidney is most susceptible to ischemic injury.
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IV. Inhibitors
In one aspect, the invention pertains to using inhibitors of
caspase-independent apoptosis. In order to investigate the
caspase-independent mechanism of apoptosis initiated by
Omi/HtrA2, specific inhibitors of its proteolytic activity were
isolated. One such family of synthetic compounds was identified and described in the Examples section. In one embodiment, the apoptosis inhibiting compound include the class of
heterocyclic compounds referred to as 1,3 diphenyl-5-(substituted)-2-thioxo-dihydropyrimidine-4,6-dione derivatives.
In a preferred embodiment, the apoptosis inhibiting compound has the general structure shown in FIG. la, where R 1 ,
depicts the various side chains which can include, but are not
limited to a nitro group, a carboxy group, a hydroxide, an
aliphatic group, an aromatic group, an acyl group, an alkoxy
group, an alkylene group, an alkenylene group, an alkynylene
group, a hydroxycarbonylalkyl group, an anhydride, an
amide, an amine, and a heterocyclic aromatic group. In a
preferred embodiment, the apoptosis inhibiting compound
has the structure shown in FIG. lb and is referred to as
"ucf-101".
In another embodiment, the apoptosis inhibiting compound has a general structure shown in FIG. 2a, where R 1 is
a nitro group, a carboxy group, a hydroxide, an aliphatic
group, an aromatic group, an acyl group, an alkoxy group, an
alkylene group, an alkenylene group, an alkynylene group, a
hydroxycarbonylalkyl group, an anhydride, an amide, an
amine, and a heterocyclic aromatic group. In a preferred
embodiment the apoptosis inhibiting compound has the structure shown in FIG. 2b and is referred to as "ucf-102".
In another embodiment, the apoptosis inhibiting compound has the general structure shown in FIG. 3a, where R 1 is
a nitro group, a carboxy group, a hydroxide, an aliphatic
group, an aromatic group, an acyl group, an alkoxy group, an
alkylene group, an alkenylene group, an alkynylene group, a
hydroxycarbonylalkyl group, an anhydride, an amide, an
amine, and a heterocyclic aromatic group. In preferred
embodiment, the apoptosis inhibiting compound has the
structure shown in FIG. 3b and is referred to as "ucf-103."
In another embodiment, the apoptosis inhibiting compound has the general structure shown in FIG. 4, where R 1 is
a nitro group, a carboxy group, a hydroxide, an aliphatic
group, an aromatic group, an acyl group, an alkoxy group, an
alkylene group, an alkenylene group, an alkynylene group, a
hydroxycarbonylalkyl group, an anhydride, an amide, an
amine, and a heterocyclic aromatic group. In preferred
embodiment, the apoptosis inhibiting compound has the
structure shown in FIG. 4b and is referred to as "ucf-104".
These class ofheterocyclic compounds showed significant
and specific activity against the protease in an in vitro assay.
The compound from this family, which exhibited the highest
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activity against Omi/HtrA2 is ucf-101. The results clearly
showed ucf-101 had a profound effect on the activity of
Omi/HtrA2 and could substantially inhibit its ability to
induce caspase-independent apoptosis in caspase-9 (-/-)null
fibroblasts. The results clearly showed ucf-101 had a profound effect on the activity ofOmi/HtrA2 and could substantially inhibit its ability to induce caspase-independent apoptosis in caspase-9 (-/-)null fibroblasts.
U cf-101 naturally fluoresces and easily enters mammalian
cells, allowing its use in in vivo experiments. The ucf-101
inhibitor can therefore be used as a tool to dissect the two
different activities (caspase-dependent versus caspase-independent) ofOmi and their respective contribution to apoptosis in various biological settings. Furthermore, ucf-101, or a
similar compound, may be useful as an anti-apoptotic drug
that would specifically target caspase-independent cell death
under clinical conditions.

dent pathway is involved, the inhibitor may act to prevent
caspase activity. Alternatively, if the capase-independent
pathway is involved, the inhibitor may inhibit the proteolytic
activity ofOmi/HtrA2 when it acts as a serine protease Inhibitors may include small molecules (organic molecules), peptides, polypeptides, and antibodies, for example. In one
embodiment, the inhibitors prevent apoptosis. Inhibitors
should have a minimum of side effects and are preferably
non-toxic.
Screening assays for inhibitors will vary according to the
type of inhibitor and the nature of the activity that is being
affected. Assays may be performed in vitro or in vivo. In
general, assays are designed to evaluate apoptotic pathway
activation (e.g., caspase protein processing, caspase enzymatic activity, serine protease activity cell viability, cell morphology changes, DNA laddering, and the like). In any of the
assays, a statistically significant increase or decrease compared to a proper control is indicative of enhancement or
inhibition. In a preferred embodiment, apoptosis is monitored
by a fluorescent method. Typically, an increase in cell viability as compared to a control indicates the presence of an
inhibitor, while a decrease in cell viability as compared to a
control indicates the presence of an enhancer.
For a caspase-independent in vitro assay, a substrate of
Omi/HtrA2 is fluorescently labeled with fluorescent marker
(e.g. FITC), and fluorescently labeled substrate is incubated
with recombinant Omi/HtrA2 (e.g., MPB-Omi 134_458 ). The
fluorescent activity of substrate is measured using a fluorescent microscopy or a fluorescemeter. As the Omi/HtrA2 protease acts on the substrate, a change in the fluorescence can be
measured. Using this fluorescent assay, inhibitor and enhancers ofOmi/HtrA2 can be used and the change in fluorescence
in the presence of an inhibitor or enhancer can be measured.
To facilitate detection using the fluorescent method with a
substrate labeled with a fluorescent marker (e.g., FITC, and
the like) the substrate can be examined by fluorescence
microscopy. Candidate compounds may be obtained from a
variety of sources. For example, they may be produced
recombinantly, purified from a natural source, or synthesized.
Alternatively, candidate molecules may be identified by
screening a library of compounds such as those available
form Nanoysn. The preferred compound will be one that is
able to inhibit apoptosis, preferably caspase-independent
apoptosis. The candidate compounds can be at least partially
purified, and most preferably, candidate compounds will be
purified to near homogeneity. Appropriate controls depend
upon the source of the candidate compound and might
include, for example, extracts from cells transfected with
control vector, or storage or reaction buffers.
For a caspase-dependent in vitro assay detecting inhibitors
and enhancers of caspase-mediated apoptosis can be performed by examining the effect of a candidate compound on
the activation of an initiator caspase (e.g., caspase 9) or an
effectorcaspase (e.g., caspases 3-7). Briefly, procaspase 9, an
IAP, cytochrome c, DATP, and an Omi peptide, polypeptide,
functional variant, or functional equivalent are provided. The
processing of caspase-9 into two subunits is assayed. Alternatively, caspase-9 enzymatic activity is monitored by adding
procaspase-3, procaspase-7, or other effector caspases to the
reaction mix and monitoring the activation of these caspases,
for example, either via subunit formation or via cleavage of a
substrate (e.g., acetyl DEVD-aminomethyl coumarin (amc),
lamin, PRPP, PARP, and the like). Typically, an increase in
processing to subunits indicates the presence of an enhancer,
while a decrease in processing to subunits indicates the presence of an inhibitor.
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V. Omi/HtrA2 Substrates

In one aspect, the invention pertains to identifying substrates involved in caspase-independent apoptosis. In particular, the identification of substrates of Omi/HtrA2. To identify
Omi/HtrA2 substrates an assay for substrates can be performed. In general, assays are designed to evaluate apoptotic
pathway activation (e.g., caspase protein processing, caspase
enzymatic activity protease activity, cell viability, cell morphology changes, DNA laddering, and the like). In any of the
assays, a statistically significant increase or decrease compared to a proper control is indicative of enhancement or
inhibition. In a preferred embodiment, apoptosis is monitored
by an electrophoresis method (e.g., 2D gel electrophoresis),
where the presence, absence or disappearance if a protein is
measured. In such an assay, cell extracts are incubated with
recombinant Omi/HtrA2 (test sample) and without Omi/
HtrA2 (control sample). After incubation, the cell extracts are
examined by electrophoresis (e.g., 2D electrophoresis). Typically, the presence of a protein in the control sample, and its
subsequent disappearance (or the degradation into smaller
fragments) in the test sample, identifies the presence of a
specific Omi/HtrA2 substrate in the cell extract. The disappearance of the protein band indicates that the protein is a
specific substrate of Omi/HtrA2 which has been degraded by
the protease activity ofOmi/HtrA2.
Using this assay, the data shown in the Examples section
identifies two substrates for Omi/HtrA2. In one embodiment,
the Omi/HtrA2 substrate is the 14-3-3 protein. In another
embodiment, the Omi/HtrA2 substrate is annexin V. The data
shows that the two polypeptides were specifically cleaved by
Omi/HtrA2 and their degradation was inhibited by the specific inhibitor ucf-101. Annexin V and 14-3-3 proteins were
shown to be involved in both apoptosis and intracellular signaling.
VI. Screening for Inhibitor or Enhancers
In one aspect, the invention pertains to identifying inhibitors of apoptosis, particularly inhibitors of caspase-independent apoptosis. In particular, the identification of inhibitors of
Omi/HtrA2. Candidate inhibitors may be isolated or procured
from a variety of sources, such as bacteria, fungi, plants,
parasites, libraries of chemicals, peptides or peptide derivatives, antibodies, and the like. Inhibitors may also be rationally designed, based on the protein structures determined
from X-ray crystallography.
Without wishing to be bound to a particular theory or held
to a particular mechanism, an inhibitor may act by preventing
Omi/HtrA2 release from the mitochondria, interfering with
Omi/HtrA2 binding to an IAP, inhibiting Omi/HtrA2 protease activity, or by other mechanisms. If the caspase depen-
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Also, for caspase-dependent apoptosis a candidate compound may be used for binding assays. A candidate compound may be added to a binding reaction with an Omi
binding molecule and recombinant Omi/HtrA2 peptide or
polypeptide, and its ability to inhibit Omi/HtrA2 binding to
an Omi-binding molecule can be determined by comparing
binding in the presence or absence of a candidate compound.
In certain circumstances, such assays will detect displacement or inhibition of binding of an Omi-binding molecule
from an Omi peptide or polypeptide.
In vivo assays are typically performed in cells transfected
either transiently or stably with an expression vector containing an Omi/HtrA2 nucleic acid molecule such as those
described herein. These cells may be used to measure caspase
processing, caspase substrate turnover, enzymatic activity of
effector caspases, or apoptosis in the presence or absence of a
candidate compound. When assaying apoptosis, a variety of
methods of cell analyses may be used, including, for example,
fluorescent spectroscopy and electro-proteins dye staining
and microscopy to examine cell viability, nucleic acid fragmentation, porosity of the cells, and membrane blebbing.
A variety of methodologies exist that can be used to investigate the effect of a candidate compound. Such methodologies are those commonly used to analyze enzymatic reactions
and include, for example, SDS-PAGE, 2D-gel electrophoresis, fluorescent spectroscopy, fluorescent microscopy, HPLC
analysis, autoradiography, chemiluminescence, chromogenic reactions, and immunochemistry (e.g., blotting, precipitating, etc.).

dispersions and sterile powders for the extemporaneous
preparation of sterile injectable solutions or dispersion. For
intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™
(BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
In all cases, the composition must be sterile and should be
fluid to the extent that easy syringability exists. It must be
stable under the conditions of manufacture and storage and
must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a
solvent or dispersion medium containing, for example, water,
ethanol, polyol (for example, glycerol, propylene glycol, and
liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for
example, by the use of a coating such as lecithin, by the
maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action
of microorganisms can be achieved by various antibacterial
and antifungal agents, for example, parabens, chlorobutanol,
phenol, ascorbic acid, thimerosal, and the like. In many cases,
it will be preferable to include isotonic agents, for example,
sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the
composition an agent which delays absorption, for example,
aluminum monostearate and gelatin.
Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a receptor protein or antireceptor antibody) in the required amount in an appropriate
solvent with one or a combination of ingredients enumerated
above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active
compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those
enumerated above. In the case of sterile powders for the
preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying
which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered
solution thereof.
Oral compositions generally include an inert diluent or an
edible carrier. They can be enclosed in gelatin capsules or
compressed into tablets. For oral administration, the agent
can be contained in enteric forms to survive the stomach or
further coated or mixed to be released in a particular region of
the GI tract by known methods. For the purpose of oral
therapeutic administration, the active compound can be
incorporated with excipients and used in the form of tablets,
troches, or capsules. Oral compositions can also be prepared
using a fluid carrier for use as a mouthwash, wherein the
compound in the fluid carrier is applied orally and swished
and expectorated or swallowed. Pharmaceutically compatible
binding agents, and/or adjuvant materials can be included as
part of the composition. The tablets, pills, capsules, troches
and the like can contain any of the following ingredients, or
compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such
as starch or lactose, a disintegrating agent such as alginic acid,
Primogel, or corn starch; a lubricant such as magnesium
stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a
flavoring agent such as peppermint, methyl salicylate, or
orange flavoring.
For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container
or dispenser which contains a suitable propellant, e.g., a gas
such as carbon dioxide, or a nebulizer.
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VII Pharmaceutical Compositions
The apoptosis inhibiting compound can be incorporated
into pharmaceutical compositions suitable for administration
to a subject, e.g., a human. Such compositions typically comprise the apoptosis inhibiting compound and a pharmaceutically acceptable carrier.
As used herein the language "pharmaceutically acceptable
carrier" is intended to include any and all solvents, dispersion
media, coatings, antibacterial and antifungal agents, isotonic
and absorption delaying agents, and the like, compatible with
pharmaceutical administration. The use of such media and
agents for pharmaceutically active substances is well known
in the art. Except insofar as any conventional media or agent
is incompatible with the active compound, such media can be
used in the compositions of the invention. Supplementary
active compounds can also be incorporated into the compositions. A pharmaceutical composition of the invention is
formulated to be compatible with its intended route ofadministration. Examples of routes of administration include
parenteral, e.g., intravenous, intradermal, subcutaneous, oral
(e.g., inhalation), transdermal (topical), transmucosal, and
rectal administration. Solutions or suspensions used for
parenteral, intradermal, or subcutaneous application can
include the following components: a sterile diluent such as
water for injection, saline solution, fixed oils, polyethylene
glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl
parabens; antioxidants such as ascorbic acid or sodium
bisulfite; chelating agents such as ethylenediaminetetraacetic
acid; buffers such as acetates, citrates or phosphates and
agents for the adjustment of tonicity such as sodium chloride
or dextrose. pH can be adjusted with acids or bases, such as
hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampules, disposable syringes or
multiple dose vials made of glass or plastic.
Pharmaceutical compositions suitable for injectable use
include sterile aqueous solutions (where water soluble) or
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Systemic administration can also be by transmucosal or
transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated
are used in the formulation. Such penetrants are generally
known in the art, and include, for example, for transmucosal
administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished
through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated
into ointments, salves, gels, or creams as generally known in
the art.
The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as
cocoa butter and other glycerides) or retention enemas for
rectal delivery.
In one embodiment, the active compounds are prepared
with carriers that will protect the compound against rapid
elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery
systems. Biodegradable, biocompatible polymers can be
used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.
Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be
obtained commercially from Alza Corporation and Nova
Pharmaceuticals, Inc. Liposomal suspensions (including
liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically
acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as
described in U.S. Pat. No. 4,522,811.
It is especially advantageous to formulate oral or parenteral
compositions in dosage unit form for ease of administration
and uniformity of dosage. "Dosage unit form" as used herein
refers to physically discrete units suited as unitary dosages for
the subject to be treated; each unit containing a predetermined
quantity of active compound calculated to produce the
desired therapeutic effect in association with the required
pharmaceutical carrier. The specification for the dosage unit
forms of the invention are dictated by and directly dependent
on the unique characteristics of the active compound and the
particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

EXAMPLES

VIII Uses
In one aspect, the invention can be used to prevent, reduce,
or ameliorate disorders associated with apoptosis. Examples
of disorders associated with apoptosis include, but are not
limited to, ischemia-reperfusion injury (e.g., stroke, myocardial infarction), heart failure-( e.g., loss of myocardiocytes );
neurodegeneration disorders-(e.g., Alzheimer's disease,
Parkinson's disease, Huntington's disease and amytrophic
lateral sclerosis); inflanmiation; osteoarthritis; human immunodeficiency virus-(loss of T lymphocytes); bacterial infection-(apoptosis-inducing virulence proteins are secreted
into the cytosol ofhost cell. e.g., Shigella species, Salmonella
species, Yersinia species and Chlamydia species); allograft
rejection and graft versus host disease; type 1 diabetes; and,
trauma (spinal-cord injury, brain injury).
Other embodiments and used of the invention will be
apparent to those skilled in the art from consideration of the
specification and practice of the invention disclosed herein.
All U.S. Patents and other references noted herein for whatever reason are specifically incorporated by reference.
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Methods and Materials
(i) Preparation ofFITC-labeled, Dephosphorylated casein
Casein-Dephosphorylated-casein (Sigma, 3 ml of2 mg/ml
stock solution) was used in a dialysis cassette (Pierce) placed
in labeling buffer (0.03 mg/ml FITC, 50 mM sodium borate,
pH 9.3, 40 mM NaCl) and kept for 48 hat 4° C. in the dark
with constant stirring. After labeling, the FITC-dephosphorylated casein (Dcasein-FITC) was further dialyzed against
50 mM Tris-HCI, pH 7.5, and 50 mM NaCl to remove any
residual unlabeled FITC. The Dcasein-FITC conjugate was
recovered from the dialysis cassette and stored at 4° C. in the
dark.
(ii) Expression and Purification ofMBP-Omi and MBP-L56
Proteases-PCR was used to amplify DNA sequences corresponding to Omi/HtrA2 (amino acids 134-458) and L56/
HtrAl (amino acids 140-480). The PCR products were
digested with Mfel and Xbal and cloned in the corresponding
EcoRI and Xbal restriction sites of pMAL-p2X vector (New
England Biolabs). MBP-Omi-(134-458) and MBP-L56(140-480) proteases were expressed in TB! Escherichia coli
(New England Biolabs) and purified on an amylase binding
affinity column as described by the manufacturer (New
England Bio labs). The concentration of purified proteases
was determined using the Bradford assay.
(iii) Expression and Purification of His-tagged Omi-(134458)
PCR was used to amplify the DNA sequence corresponding to Omi/HtrA2 (Omi-(134-458)). The PCR product was
cloned in-frame in the bacterial expression vector pET-28
(Novagen). For bacterial expression, BL21 (DE3) (Novagen)
bacteria were transformed with pET-Omi-(134-458). Single
colonies were grown overnight in LB medium containing
kanamycin. The overnight culture (1 ml) was used to inoculate I liter of LB medium, and growth was continued at 3 7° C.
until the A 600 was -0.8. At this time, 1 mM mist isopropyl1-thio-~-D-galactopyranoside was added, and the culture was
placed in a shaking incubator overnight at 20° C. Bacteria
were harvested by centrifugation and lysed in a buffer containing 20 mM Tris-HCI, pH 7.5, 500 mM NaCl, 100 µg/ml
lysozyme, and a protease inhibitor mixture (Sigma). The
bacterial suspension was then sonicated, and the soluble fraction was purified using nickel-nitrilotriacetic acid His-Bind
resin (Novagen). The purity of the HisOmi-(134-458) protein
was monitored by SDS-PAGE and Coomassie Blue staining
of the resulting gel.
(iv) Proteolytic Activity ofOmi Using Dcasein-FITC as Substrate
Opaque microtiter plates (coming Glass) were used in
order to minimize background absorbance. A typical assay
included 10 µg of Dcasein-FITC substrate, 2 µg of MBPOmi-(134-458) in assay buffer (20 mM Na 2 HP04 /NaH 2 P04 ,
pH 7.4, 200 mM NaCl, 5% glycerol) in a final volume of 100
µ!. Dcasein-FITC conjugate solution (50 µl of a 0.2 µg/µl
stock solution) was added in each well using a Multidrop 384
multiple dispenser (Lab systems) and incubated in the Wallac
1420 Victor Multilabel counter at 37° C. for 15 min. After
this time, 50 µl of MBP-Omi-(134-458) protease (40 ng/µl)
was added to each well. The fluorescence (535 nm) of the
reactions was recorded every 5 min for a 30-min period.
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(v) Combinatorial Library Screening
A Pharma Library Collection from Nanoscale Cominatorial Synthesis Inc., 625 Clyde Ave, Mountain View, Calif.
94943-2213 was screened for compounds, which may inhibit
the proteolytic activity ofMBP-Omi-(134-458) in an in vitro
assay. Each compound, (from a total of 528 compounds) 10
µM final concentration, was preincubated with 50 µl ofMBPOmi-(134-458) (2 µg) for 15 min at 37° C. After this time,
Dcasein-FITC solution (10 µg) was added, and the change in
fluorescence was read every 5 min during a 30-min period
using a 535-nm bandpass filter. The proteolytic activity of
MBP-Omi-(134-458) was expressed as the percentage inhibition, where 100% refers to the activity in the absence of
inhibitor (Me 2 SO replaced the inhibitor in the assay).

fXa fluorogenic (20 µM), rat FXa (5 nM), spectrozyme fXa
fluorogenic (25 µM), rabbit FXa (5 nM), spectrozyme FXa
fluorogenic (15 µMr), kallilkrein (5 nM), kallikrein fluorogenic substrate (50 µM), trypsin (2.5 nM), Chromozym X
(150 µM), plasmin(5 nM), I-1045 (100 µM)thrombin( 4nM),
Chromozym PL (150 µM), FVIIa/tissue factor (15 nM/3 nM),
Chromozym t-PA (500 µM), t-PA (100 nM), I-1140 (200
µM), u-PA (3 nM), I-1140 (150 µM), activated protein C (5
nM), and protein C-activated substrate (100 µM) in a final
concentration of 5% Me 2 SO. All enzymatic assays were carried out at room temperature in 384-well microtiter plates
(Nurre). Color development due to the release of p-nitroanilide from the chromogenic substrates was monitored continuously for 20 min at 405 nm on a Tecan SpectraFluorPlus
microtiter plate reader (Tecan). fluorescence from the release
of the coumarin derivative, aminomethylcoumarin, was measured at excitation 360 nm/emission 465 nm on the same
reader. The IC 50 values were calculated using the GraFit 4
program (Erithacus Software).

(vi)Activity of Several ucfAnalog Compounds against MBPOmi-(134-458)
The assay was performed as described above using
Dcasein-FITC as substrate. 2 µg ofMBP-Omi-(134-458) was
incubated with various concentrations of ucf-101, ucf-102,
ucf-103, or ucf-104 for 15 min. After this time 10 µg of
Dcasein-FITC substrate was added, and the reaction proceeded for an additional 30 min. The activity ofMBP-Omi(134-458) was monitored at 535 nm.
(vii) Determination of IC 50 for ucf-101 and ucf-102.
The IC 50 value for each of the two selected inhibitors was
obtained using His-Omi-(134-458) and the EnzCheck assay
kit (Molecular Probes) that contains BODIPY FL-casein as a
generic substrate. Briefly, 35 µl of His-Omi (134-458) (500
nM) diluted in 20 mat Na 2 HP04 /NaH 2 P04 , pH 7.4, 200 mM
NaCl, 5% glycerol was incubated with 5 µl of various concentrations of the inhibitors (0.1-1000 µM) in 100% Me2 SO
(final concentration ofMe 2 SO was 10%); 10 µl ofBODIPYFL casein (2.5 µM final concentration) diluted in buffer was
added. The assay was carried out using 384-well microtiter
plates. Fluorescence was monitored continuously for 10 min
at 3 7° C. on a Tecan SpectraFluorPlus microtiter plate reader
(Tecan, Crailsheim, Germany) at an excitation wavelength
485 nm/emission wavelength 530 nm. IC 50 values were calculated using the GraFit 4 program (Erithacus Software,
Middlesex, UK).
(viii) Activity of ucf-101 Against Various Serine Proteases
The amount of the inhibitor giving a 50% (IC 50 ) decrease
of the enzyme activity compared with the control reaction
was estimated for various serine pro-teases. Briefly, 35 µl of
the indicated enzyme diluted in the corresponding buffer was
incubated for 10 min with 5 µl of various concentrations of
inhibitor(0.1-1000 µM) in50% Me 2 50, 50% buffer.After this
time, 10 µl of the corresponding peptidic colorimetric or
fluorogenic substrate diluted in buffer was added. In the case
of the FVIIa/TF assay, a preincubation of both proteins for 10
min at room temperature was performed prior to addition of
the inhibitor to allow complex formation. For this experiment
the following materials were used: canine FXa, rat FXa, and
rabbit FXa (Enzyme Research Laboratories); trypsin from
bovine pancreas and human thrombin (Sigma); human plasmin, human t-PA, human t-PA, and human kallikrein (Calbiochem-Novabiochem); human APC and recombinant
human factor VIIa (American Diagnostica ); and recombinant
tissue factor (Dade Behring). The substrates used are as follows: spectrozyme FXa fluorogenic (American Diagnostica);
kallilkrein fluorogenic substrate; protein C-activated substrate (Calbiochem); Chromozym X, Chromozym Pl, and
Chromozym t-PA (Roche Diagnostics); I-1045, I-1140, and
I-1140 (Bachem).
The amount of each enzyme and its corresponding substrate used in the assay was canine FXa (2 nM), spectrozyme
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(ix) Subcellular Localization ofucf-101
HeLa cells were grown on coverslips using F-12 (Ham's)
nutrient mixture (Invitrogen) supplemented with 10% fetal
calf serum (Sigma), 2 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin (Invitrogen). Different
concentrations ofucf-101 were added to the cell media, and
after 2 h cells were washed three times with phosphate-buffered saline and fixed with 4% paraformaldehyde. The coverslips were then placed on glass slides using Fluoromount-G
solution (Southern Biochemical Association). The subcellular localization ofucf-101 was monitored using a LSM510
confocal laser-scarming microscope (Zeiss).
(x) ucf-101 Inhibits Omi-induced Caspase-independent Apoptosis in Caspase-9-/-) Null Fibroblasts-Caspase-9(-/-)
cells were transfected with either pEGFP-Nl vector (Clontech) or M-Omi-GFP that encodes a cytoplasmic form of
Omi/HtrA2 (Hegde et al (2002)J. Biol. Chem. 277, 432-438).
Transfected cells were kept in medium containing different
concentrations of ucf-101. This medium, including the
inhibitor, was replaced every 12 h. After 36 h, cells were
stained with propidium iodide and 4',6-diamidino-2-phenylindole as described (Hegde et al (2002)J. Biol. Chem. 277,
432-438). Normal and apoptotic GFP-expressing cells were
counted using fluorescence microscopy.
HeLa cells were transfected with mature Omi (aa134-458),
Omi-A VPS-GFP and mature Omi where the first Alanine (A)
was mutated to a Glycine. Omi-GVPS-GFP transfected cells
were treated with increasing concentration of ucf-101. Overexpression of mature Omi-GVPS-GFP can induce apoptosis
only through its ability to function as an active protease
(caspase-independent pathway). ucf-101 inhibited the protease activity and apoptosis.
(xi) Kidney Ischemia/Reperfusion
Kidney ischemia/reperfusion experiments were performed
using Balb/c male mice, 20-25 grams, which were anesthetized with sodiumpentobarbital (65 mg/kg) i.p. and undergo
uninephrectomy of the left kidney followed 24 h later by
ischemia of the right kidney. This is done by placement of a
microaneurysm clamp on the renal artery and vein for 30 min
followed by reperfusion (104). Kidneys were harvested 1, 24,
and 48 h after reperfusion.
In bilateral ischemia experiments, ischemia were performed for 30 min followed by reperfusion (Kelly, et al.
(1996) J Clin Invest, 97, 1056-63). Kidneys will be harvested
at the same time points as with nephrectomy/unilateral
ischemia. Equal amounts of protein extracts from control and
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post-ischemic kidneys will be resolved and analyzed by SDSPAGE. The level ofOmi/HtrA2 protein will be determined by
Western blot analysis using a specific antibody (Hegde, et al.
(2002) J. Biol Chem, 277, 432-8; and Faccio, et al. (2000) J.
Biol. Chem., 275, 2581-8).

ice-cold acetone. Non-specific binding was blocked with 2%
BSA in PBS and, subsequently, cells were stained using a
rabbit anti-Omi and a mouse anti-gp330 antibodies at room
temperature for 2 hours. After three washes with PBS, secondary antibodies cy3 conjugated anti-rabbit and Oregongreen conjugated anti-mouse was added for one hour. Finally,
the cover slips were washed and placed on microscope slides
using Fluoromount-G as the mounting solution. Slides were
observed using a LSM510 confocal laser scanning microscope (Zeiss).

(xii) Immunohistochemistry
Kidneys from control or post-ischemic mice were briefly
perfused in situ via the heart with PBS (0.9% NaCl in 10 mM
sodium phosphate buffer, pH 7.4 ), followed by 2% paraformaldehyde, 70 mM lysine, and 10 mM sodium periodate (PLP)
and fixed as (Breton, et al. (1998) J Am Soc Nephrol, 9,
155-66). Kidney slices were immersed in 30% sucrose then
frozen in liquid nitrogen Semi thin (1 mm). Sections were cut
from tissue embedded in LX-112 and treated for 2 minutes
with a mixture of 2 g KOH, 5 ml propylene oxide, and 10 ml
methanol to remove the resin. Alternatively, 1 and 5 mm
cryostat sections were used. Sections will be incubated for 10
min in PBS containing 1% BSA to reduce non-specific background staining, followed by a 2-hour incubation at room
temperature with a 20-1 drop of specific antibody. After 3x5min rinses in PBS, sections were incubated for 1 h with goat
anti-rabbit IgG coupled to fluorescein isothiocyanate (Calbiochem-Behring Corp., San Diego, Calif.), and diluted 1:30
for detection of antigenic sites by immunofluorescence
microscopy. Sections were then rinsed 3x5 min in PBS and
mounted in Gelvatol containing 4% n-propyl gallate (Sigma
Chemical Co., St. Louis, Mo.) to retard quenching of the
fluorescence. Photographs of sections were taken on Kodak
TMAX film using a Nikon FXA photomicroscope with epifluorescence. Some sections were also analyzed using the
ABC-peroxidase procedure. After incubation with the primary IgG, a biotinylated goat anti-rabbit IgG (Vector Laboratories, Burlinghame, Calif.) were applied to sections for 1
hour, followed by the ABC reagent (also from Vector Laboratories) for a further 1 hour. Peroxidase was revealed with
diaminobenzidine and H 2 0 2 , and the sections dehydrated in
ethanol and mounted in Permount (Fisher Scientific Co.).
(xiii) Cell Culture
HK-2 cells were grown in DMEM/HamF12 media supplemented with 10% FCS, hydrocortisone (0.4 µg/ml), insulin,
transferring and sodium selenite (all used at a final cone. 5
µg/ml). LLC-PKl cells were grown in DMEM plus 10% FCS
and MDCK in MEM plus 10% FCS.
(xiv) Isolation of Mouse Primary Kidney Proximal Tubular
(MPT) Cells
MPT cells were isolated from collagenase-digested fragments derived from the cortices of kidneys ofC57BL6 mice
as described (Sheridan, et al. (l993)AmJ Physiol, 265, F34250; and Kroshian, et al. (1994) Am J Physiol, 266, F21-30).
MPT cells were grown in serum-free medium ( 1: 1 mixture of
Dulbecco's modified Eagle's medium (DMEM) and Ham's
F-12) containing 15 mM Hepes, 5 µg/ml insulin, 50 nM
hydrocortisone, 5 µg/ml apotransferrin, 50 µg/ml penicillin,
and 50 µg/ml streptomycin. The cells were used between the
5th and 10th day after culture.
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(xvi) ATP Depletion ofMPT Cells Using Chemical Anoxia
MPT cells were incubated in dextrose-free DMEM at 37°
C. in a humidified atmosphere containing 5% C0 2 -95% air.
For control monolayers, not subject to ATP depletion, dextrose (10 mM) will be added to the DMEM medium. ATP
depletion of varying severity was induced using 2 mM antimycin (Sigma) or 5 mM 2-deoxyglucose (DOG) (Sigma)
with and without varying concentrations of dextrose. Antimycin alone causes the most severe ATP depletion and
induces cell death by necrosis. DOG alone causes intermediate ATP depletion and induces apoptotic cell death (95). Six
different metabolic conditions were used: 1) antimycin alone,
2) antimycin+0.25 mM dextrose, 3) antimycin+l mM dextrose, 4) DOG alone, 5) DOG+4 mM dextrose, and 6) DOG+
10 mM dextrose.
(xvii) Cisplatin-InducedApoptosis
MPT cells was plated in serum-free medium [1: 1 mixture
of DMEM and Ham's F-12] (GIBCO) containing 2 µM
glutamine, 50 U/ml penicillin, 50 mg/ml streptomicyn
(GIBCO), 15 mM HEPES, 5 mg/ml transferring, 5 mg/ml
insulin and 50 nM hydrocortisone (Sigma). Medium was
replaced every 2 days and the cells were used 6 to 8 days later.
The MPT cells were incubated with various concentrations
(10, 20, 50, and 100 mM) of cisplatin or vehicle (methylformamide) for 48 hours and analyzed by Flow Cytometry, or
extracts were prepared for Western blot analysis.
(xviii) Induction ofApoptosis onHK-2 Cell Line Using H 2 0 2
HK-2 cells were cultured in DMEM medium containing 2
mM glutamine, 50 U/ml penicillin, 50 µg/ml streptomycin
(GIBCO), 15 mM HEPES, 5 mg/ml apotransferrin, 5 mg/ml
insulin and 50 nM hydrocortisone. Approximately 90% confluent cells were treated with various concentrations ofH 2 0 2
(10, 20, 50, 100 µM) for 18 hours. Whole cell extracts were
prepared and analyzed by Western blot analysis using Omi/
HtrA2 antibodies.
(xix) Use of siRNAs to Suppress Omi/HtrA2 Expression in
Proximal Tubular Cells
The pSuppressor2 vector available from Imgenex (San
Diego, Calif., Paul, et al. (2002) Nat Biotechnol, 20, 505-8)
was used to stably express the small interfering RNA (siRNA)
that is homologous to Omi/HtrA2 mRNA sequence.
A double stranded (ds) oligo with the following sequence was
used:

5'-TCGAATTCGCTGGGGGAGGAGACagtactGTCTCCTCCCCCAGCGAATTTTT-3'

(SEQ ID NO, 2)

3'-TAAGCGACCCCCTCCTCTGtcatgaCAGAGGAGGGGGTCGCTTAAAAATCTAG-5'

(SEQ ID NO, 3)

(xv) Confocal Microscopy
Mouse proximal tubular cells were grown for 6 days on
microscope cover slides. Adherent cells were washed in PBS,
fixed in 4% paraformaldehyde and made permeable using

65

This double stranded oligo encodes 19 base pairs representing sequence 51-70 nucleotides downstream of the initiation of translation of Omi/HtrA2. The sense and antisense
sequence is separated by a stem loop of 6 nucleotides that
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encodes the Sea I restriction site used for easy identification
of the insert. The double stranded oligo was cloned into the
corresponding sites of the pSupressor2 vector and bacterial
clones was screened by isolating plasmid DNA followed by
restriction digest with Sea I restriction enzyme. Positive
clones will have their plasmid DNA sequenced as described
by Faccio, et al. ((2000) J. Biol. Chem., 275, 2581-8). The
pSuppresor/Omi clone was used to transfect HK-2 cells. The
vector has the NeoR gene and permanent cell lines can be
made using G418 (Invitrogen) in the culture medium. The
effectiveness of this siRNA to suppress expression of the
Omi/HtrA2 will be monitored by Western blot analysis using
total cell extracts and anti-Omi antibodies. As a control, cell
lines were made using the pSuppressor2 vector alone.

(Pall Corporation) using a Semi-Dry Transfer Blot (Bio-Rad).
Non-specific binding was blocked using 2% nonfat dry milk
in TBST to saturate the membrane. The blot was then incubated with an anti-GFP monoclonal antibody (Santa Cruz
Biotechnology), 1:700 dilution followed by a secondary
horseradish peroxidase-conjugated goat anti-mouse antibody
(Jackson ImmunoResearch), 1: 15000 dilution, and visualized by chemiluminescence (ECL) using a SuperSignal West
Pico substrate (Pierce).

(xx) Cell Viability Assay
The viability of cells was monitored using the MTT assay
(Buttke, et al. (1993) J Immunol Methods, 157, 233-40; and
Mossman, (1983) Environ Health Perspect, 53, 155-61 ). The
assay is based on the ability of the mitochondria of viable
cells to cleave the tetrazolium rings of the pale yellow MTT
dye to form dark blue formazan crystals. The amount of
formazan product produced is directly proportional to the
number of viable cells present in the culture well. After
removal of the medium, MTT (1 µg/ml) is added to each well
and incubated at 37° C. for 4 hours. The formazan crystals
formed by viable cells are then dissolved by adding 10%
SDS/O.OlN HCl to each well and incubating overnight. The
absorbance of aliquots from each well will be read by 1420
Multilabel counter Victor2 (Wallac) plate reader with a test
wavelength of 570 nm and a reference wavelength of 650 nm.
Percent viability will be expressed as the absorbance of ATPdepleted cells with the ucf-101 inhibitor/absorbance of ATPdepleted cells without the inhibitor, where DMSO is added
instead.
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Activity of Omi Protease Against Dcasein-FITC
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(xxi) Transfection of Mammalian Cells
60% confluent cells were transfected using the Lipofectamine Plus Reagent according to the instructions provided by the manufacturer (Life Technologies).
(xxi) Quantitative Real-Time PCR Analysis of Omi/HtrA2
mRNA.
Total RNA was isolated from MPT cells using the QIAgen
RNeasy kit following manufacturer's instructions. 2 µg of
total RNA was transcribed into cDNA using the Omniscript
reverse transcriptase (QIAgen). Real-Time PCR was performed with AmpliTaq Gold polymerase in a iCycler realtime PCR thermocycler (BioRad) and the Sy Br Green detection protocol as per the manufacturer's instructions. Briefly,
12 ng of total cDNA, 50 nM of each primer and 1xSyBr Green
mix was used in a total volume of 25 µ!.The primer sequences
for murine Omi/HtrA2 are: Sense 5'-GCGGGGCGGGGTGCAAAC-3' (SEQ ID NO: 4) and antisense 5'-GACAGCCAGCACCGTGG-3' (SEQ ID NO: 5). Murine b-actin primers: sense 5'-TTCGTTGCCGGTCCACA-3' (SEQ ID NO: 6)
and antisense 5'-ACCAGCGCAGCGATATCG-3' (SEQ ID
NO: 7). Samples were read in triplicate and normalized for
expression of ~-actin RNA.
(xxii) Western Blot Analysis
For Western blot analysis, cells were harvested 24 hours
after transfection, washed and lysed using a Triton X-100
based buffer (1% Triton X-100, 10% Glycerol, 150 mM
NaCl, 20 mM Tris-HCl pH 7.5, 2 mM EDTA) containing a
protease inhibitors cocktail (Roche). Approximately 30 µg of
the whole cell extracts were re-suspended in SDS-sample
buffer and boiled for 3 minutes. The samples were resolved by
SDS-PAGE and electro-transferred onto PVDF membranes

(xxiii) Flow Cytometry
Cells were grown on 6 well plates using appropriate media.
60% confluent cells were transfected with various constructs
using Lipofectamine Plus Reagent according to the instructions provided by the manufacturer (Life Technologies). The
transfected cells were detached 48 hours later, washed twice
with ice-cold PBS, resuspended in lx binding buffer (BD
Bioscience) and stained with PE-conjugated annexin V
according to BD Bioscience protocol. Analysis of GFP and
annexin V positive cells will be performed on a FACS Vantage
Flow Cytometer (Becton Dickinson).
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This example demonstrates the activity of Omi protease
against Dcasein-FITC. As no physiological substrates for
Omi protease are known, ~-casein was used as a generic
substrate in in vitro assays to monitor the protease activity of
Omi. For high throughput screening, a new assay was developed that uses a mixture of a-casein, ~-casein, and dephosphorylated casein (Dcasein) coupled to FITC, as a substrate,
The use of Dcasein-FITC increases the fluorescence during
the reaction with less fluctuation and lower background (data
not shown). A typical assay uses 10 µg of Dcasein-FITC and
2 µg MBP-Omi-(134-458) in 100 µl of reaction buffer (20
mM sodium phosphate buffer, pH 7 .5, 200 mMNaCl, and 5%
glycerol) at 37° C. for 30 min.
The results show that there was a rapid increase in fluorescence for the first 20 min followed by a slower increase forthe
remaining 10 min of the assay. Various concentrations of
substrate, Dcasein-FITC, as well as MBP-Omi-(134-458)
were used for kinetic studies.
Example 3

50

Combinatorial Library Screening

55

60
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By using an in vitro high throughput assay system, a combinatorial library of synthetic compounds (Nanosyn) was
screened. This collection represented compounds that had
commonly accepted pharmaceutical hit structures with possible pharmacological properties. The assay was performed
in multiple 96-well plates. The inhibition activity of each
compound was expressed as the percentage of relative fluorescence change (decrease) compared with the control (no
compound). The final concentration of each compound tested
was 10 µM. Fifty two compounds showed more than a 20%
inhibition of MBP-Omi-(134-458) activity in the initial
screening, but only one compound (ucf-101) showed greater
than a 50% inhibition at the concentration tested after two
rounds of screening and selection (Table III).
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TABLE III
Screening for inhibitors oftbe proteolytic activity ofOmi
A combinatorial library of 528 selected compounds was used in a higb
tbroughout screening for potential inhibitors oftbe proteolytic activity of
Omi. Several compounds had weak activity against Omi, but after two
rounds of selection only one chemical showed substantial and
reproducible inhibition against Omi in the assay used.
% inhibition

1st screening

5

2 screening

10
0
1-19
20-39
40-59
Total

468
52
2

-

528

26
47

-

1
75

15

of ~-casein substrate. (Lane 1, ~-casein control; lane 2, HisOmi+~-casein, digested for 15 min; lane 3, His-Omi+~
casein, digested for 30 min; lane 4, His-Omi+lOO µM ucf101+/~-casein; lane 5, His-Omi+80 M ucf-101+~-casein;
lane 6, His-Omi+50 µMucf-101+~-casein; lane 7, His-Omi+
30 µM ucf-101+~-casein; lane 8, His-Omi+20 µM ucf-101+
~-casein; lane 9, His-Omi+ 1OpM ucf-101 +~-casein; and lane
10, prestained molecular weight marker.)
FIG. 8 shows that bacterially made His-Omi-(134-458)
had substantial activity against ~-casein, and after 30 min
total degradation of the substrate occurred. ucf-101 inhibited
His-Omi-(134-458) activity in a concentration-dependent
manner (lanes 4-9) when assayed for 30 min with 200 ng of
His-Omi-(134-458) and 5 µg of ~-casein. ucf-101 (80 µM)
was able to inhibit completely the activity of 200 ng of HisOmi-(134-458) (lane 5).

Example 4
Inhibition of the Proteolytic Activity of
MBP-Omi-(134-458) Using ucf-101 and Various
Analogs
Several analogs ofucf-101 were obtained, and the chemical structures are shown in FIGS.1-4. The activity of these ucf
analogs was tested using MBP-Omi-(134-458) in the same in
vitro assay system. FIG. 7 shows the inhibition ofMBP-Omi(134-458) by ucf-101 and several other ucf analogs. The
assay was performed with 10 µg ofDcasein-FITC incubated
with 2 µg ofMBP-Omi-(134-458) in the presence of various
concentrations of ucf-101 and three analogs, ucf-102, ucf103, and ucf-104. •, ucf-101; .._, ucf-104; e, ucf-103; +,
ucf-102. All three analogs inhibited the proteolytic activity of
MBP-Omi-(134-458) but to a lesser extent than ucf-101. ucf104 (20 µM) inhibited 58% MBP-Omi-(134-458) activity,
whereas the same concentration of ucf-101 inhibited more
than 78% MBP-Omi-(134-458) activity. When MBP-Omi(134-458) was preincubated with various concentrations of
ucf-101, -102, -103, and -104 at 37 C. for longer periods (40
mill or 1 h) inhibition was reduced, indicating the inhibitors
did not irreversibly bind the enzyme (results not shown).
MBP-Omi-(134-458) was also incubated with various
amounts ofDcasein-FITC in the presence of 10 µM ucf-101.
The rate of the reaction decreased by 50% when the concentration of the substrate was doubled and even reached the rate
of the control reaction at higher concentrations of DcaseinFITC (results not shown). These results suggest ucf-101 is a
competitive inhibitor of Omi protease.
Example 5

Example 6
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Comparison of the Proteolytic Activities of His-Omi
(134-458) and His-L56-(156-480)
Proteins-OmiHtrA2 and L56/HtrA1 are members of the
same family of mammalian serine proteases with extensive
homology in their catalytic domains (Faceio et al. (2000) J.
Biol. Chem. 275, 2581-2588). Bacterially made His-Omi(134-458) and His-L56-(140-480) was used to investigate
whether ucf-101 was able to inhibit the activity ofHis-L56140-480) in a similar manner. FIG. 9 shows the inhibition of
the proteolytic activity of MBP-Omi-(134-458) and MBPL56-(140-480) by ucf-101. The assay was performed with 10
jig ofFITC-Dcasein and 2 µg ofMBP-Omi-(134-458) (MBPOmi) or MBP-L56-(140-480) (MBP-L56) in the presence of
various concentrations ofucf-101. The increase in fluorescence for the initial 20 min was used for comparing the
activities of MBP-Omi-(134-458) or MBP-L56-(140480). +, MBP-Omi; •MBP-L56.
FIG. 9 shows ucf-101 is an effective inhibitorof the activity
of His-L56-(140-480) but to a lesser extent than His-Omi(134-458).
Example 7
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IC 50 ofucf-101 Against Various Serine Proteases
The enzymatic activity of His-Omi and the determination
of the IC 50 for ucf-101 and ucf-102 were performed as
described in Example 1 (vii). These values are shown in Table
IV. ucf-101 hadanIC 50 of9.5 µM, and ucf-102 hadanIC 50 of
45.9 µM.

Assay ofHis-Omi-(134-458) Activity Using
Unlabeled ~-Casein and SDS-PAGE Analysis
The inhibitory effect ofucf-101 on the activity ofHis-Omi(134-458) was monitored by incubating inhibitor and enzyme
together for 10 min at room temperature prior to the addition
of ~-casein as a generic substrate. An in vitro assay of the
proteolytic activity ofHis-Omi-(134-458) in the presence of
different concentrations of ucf-101 was performed, and the
results shown in FIG. 8. The assay was performed at 37° C.,
and after the indicated time points the reactions were resolved
on SDS-PAGE and the gel stained with Coomassie Blue. Omi
(200 ng) was incubated with 5 µg of~-casein substrate in a 20
µl reaction volume for 30 min at 37° C. The ucf-101 compound was preincubated with His-Omi-(134-458) (His-Omi)
protease for 10 min at room temperature prior to the addition

TABLE IV
55

IC 50 ofucf-101 and ucf-102 inhibitors on His-Omi
The value is the average from three independent experiments.
Inhibitors
ucf-101
ucf-102

9.5
45.9

60

65

The specificity of ucf-101 was determined using several
unrelated serine proteases. Their susceptibility to inhibition
by ucf-101 was tested. The IC 50 values for ucf-101 inhibitor
from these experiments are shown in Table IV. These results
suggest ucf-101 has very high specificity for the Omi protease.
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TABLE IV
IC 50 values ofucf-101 on various protease
The two IC 50 values are derived from two independent experiments.
The two IC 5a values are derived from two independent experiments.

IC 50 inµM

Protease
Canine-Fxa

Rat-Fxa
Rabbit-Fxa
Hu-kallikrein
Bovine-trypsin
Hu-plasmin
Hu-tbrombin
Hu-rec.-FVIIa
Hu-t-PA
Hu-u-PA
Hu-APC

430
360
410
>500
260
300
200
250
>500
>500
>500
400
>500
>500
>500
>500
390
390
500
500
500
500
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Example 8
Intracellular Localization of ucf-101
To investigate the potential use of ucf-101 inhibitor in in
vivo experiments, the ability of the inhibitor to enter mammalian cells was tested. ucf-101 has natural fluorescence at
543 nm that was used to detect the presence of the compound.
HeLa cells were treated with different concentrations ofucf101 and observed by confocal microscopy. Intense red fluorescence, due to the presence ofucf-101, was observed in the
cytoplasm of the treated cells.
The cytoplasmic localization of ucf-101 was examined
when subconfluent HeLa cells were treated with 50 (A), 40
(B), and 20 µM (C) ucf-101 and were observed using a confocal microscope. A-C show cytoplasmic red staining due to
the presence of ucf-101, indicating cells are permeable to this
chemical. No staining was seen when Me 2 SO alone was used.
D (results not shown)
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Example 9
50

ucf-101 Can Inhibit Omi-Induced
Caspase-Independent Apoptosis
The inhibition of Omi-induced caspase independent cell
death by ucf-101 was examined. Mouse embryo caspase-9
(-/-/-)null fibroblasts (Hakem et al. (1998) Cell 94; 339352) were transiently transfected with pEGFP-Nl (control)
or Omi-GFP (Hegde et al, Supra). The transfected cells were
kept in medium containing different concentrations of ucf101. The percentage of apoptotic cells in the transfected
population was determined after 36 has described by Hakem
et al. (1998), Supra.
Cytoplasmic expression of M-Omi-GFP induced apoptosis in -70% of the transfected cells. When cells were treated
with increasing concentrations ofucf-101, it was found that
increasing the concentration of inhibitor up to 10 µM gradually reduced Omi-induced apoptosis up to 40%. ucf-101 had
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no effect on the control (vector alone) transfected cells. When
the concentration of the ucf-101 increased to 25 µM, the
anti-apoptotic activity of the inhibitor was compromised due
to a cytotoxic side effect that caused apoptosis both in the
M-Omi-GFP, as well as control transfected cells (FIG. 10).
Collectively, these results demonstrate that Omi/HtrA2 is a
mitochondrial serine protease that is released to the cytoplasm upon induction of apoptosis. In the cytoplasm, Omi
binds to XIAP and relieves its inhibition of caspase-9 (Suzuki
eta!. (200l)Mol. Cell. 8, 613-621; Hegde et al. (2002)J. Biol.
Chem. 277, 432-438; and Verhagen et al., (2002) J. Biol.
Chem. 277, 445-454). In this respect, Omi acts in a manner
similar to Smac/DIABLO, another mitochondrial protein that
also binds to XIAP (Du et al. (2000) Cell 102, 33-42; and
Verhagen et al., (2000) Cell 102, 43-53). This interaction with
XIAP is mediated via an AVPS motif that is exposed at the
amino terminus of mature Omi protein after processing (Suzuki et al. Supra, Hegde et al. Supra).
Omi/HtrA2 is also able to induce apoptosis in a caspaseindependent manner that exclusively relies on its ability to
function as a protease (Suzuki et al. (2001) Mal. Cell. 8,
613-621; Hegde et al. Supra; Martins et al. (2002) J. Biol.
Chem. 277, 439-444; Verhagen et al. Supra; and van Loo et al.
(2002) Cell Death Differ. 9, 20-26). This caspase-independent pathway is not well understood; its contribution to overall cell death is not known, and the role of Omi as a protease
in this pathway is not clear. Because the caspase-independent
pathway relies on the ability of Omi/HtrA2 to function as a
protease, it suggests that proteolytic cleavage of specific proteins is involved. This cleavage might inactivate and remove
apoptotic inhibitors, or it may activate precursor proteins
whose function might be necessary for caspase-independent
cell death.
In order to investigate the contribution of the proteolytic
activity of Omi to its overall pro-apoptotic function, specific
inhibitor(s) of its activity were screened. One such specific
inhibitor was identified and called ucf-101. This heterocyclic
compound was able to inhibit the proteolytic activity of Omi
in vitro in a very specific and reversible manner. The specificity ofucf-101 was tested against a panel of several unrelated serine proteases, and no significant activity was
detected. When L56/HtrA1 was used in the same assay, ucf101 showed specific inhibition against this protease. L56/
HtrAl belongs to the same family of proteases as Omi, and
they both share extensive homology throughout their respective catalytic domains (Faceio et al. (2000) J. Biol. Chem. 27 5,
2581-2588). The normal functionofL56/HtrA2 is not known,
and unlike Omi that localizes to mitochondria, L56 is secreted
(Ru et al. (1998) J. Biol. Chem. 273, 34406-34412). The
natural fluorescence ofucf-101 was used to monitor its ability
to enter mammalian cells. This property is necessary for
ucf-101 to be useful for in vivo experiments designed to test
inhibition of Omi that is intracellular.
To test the ability of ucf-101 to inhibit the proteolytic
activity of Omi in vivo, an assay was used where transient
overexpression of a cytoplasmic form of Omi induces
caspase-independent cell death (Hedge et al, supra). The cells
used in this assay were caspase-9 (-/-)null mouse embryonic
fibroblasts (Hakem et al. supra)) in which over-expression of
a cytoplasmic form ofOmi can induce the caspase-independent pathway of apoptosis. This form of cell death caused by
Omi relies entirely on its ability to function as a protease.
Therefore, ifucf-101 blocks the activity ofOmi, it will interfere with apoptosis of the caspase-9 (-/-)mouse embryonic
fibroblasts. When these fibroblasts were transfected with the
vector encoding the cytoplasmic Omi and treated with ucf101, apoptosis was dramatically reduced.
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Example 10

identified by staining with anti-gp330 also stained positive
with anti-Omi/HtrA2 (data not shown).

Omi/HtrA2 is Predominantly Expressed in the
Proximal Kidney Tubules
To determine the expression profile of Omi/HtrA2 in kidney cells, immunocytochemical staining for Omi/HtrA2 was
performed as described (Faccio et al. (2000). J. Biol. Chem.,
275, 2581-8 and Park, et al (2002) J. Biol Chem, 277, 20409)). Human kidney sections were obtained from Biochain
Institute Inc. (Hayward, Calif.) and mouse sections were prepared as previously described (Faccio et al (2000 Supra).
Omi/HtrA2 antiserum was raised against bacterially made
His-tagged Omi/HtrA2 protein (residues 134-458) and affinity purified (Hegde, et al (2002) Supra). Proximal tubules
were identified by apical staining with anti-gp-330 (also
known as megalin) (green) (Kerjaschki, et al (1982) PNAS,
79, 5557-81). Omi/HtrA2 protein expression was indicated
by red staining; when both images are merged there was
extensive co-localization of gp330 and Omi/HtrA2. Both
human and mouse kidney sections showed the same expression profile.

Example 13

Subcellular Localization ofOmi/HtrA2 in Normal
and Apoptotic MPT Cells
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Example 11
Expression of Omi/HtrA2 is Upregulated After
Ischemia/Reperfusion
To show that Omi/Htra2 was upregulated after ischemia/
reperfusion, Balb/c male mice underwent uninephrectomy of
the left kidney and, 24 hours later, ischemia was induced on
the right kidney for 30 min followed by reperfusion (Park, et
al. (2002) J. Biol Chem., 277, 2040-9). Kidneys were harvested 90 min and 24 hours after reperfusion and processed as
described in Example 1 (xi). Sections of mouse kidneys
showed a substantial increase in the intensity of Omi/HtrA2
staining 90 min and 24 hours after ischemia/reperfusion as
compared with sham perated kidneys withAnti-Omi having a
red fluorescence and anti-gp330 having a green fluorescence
(data not shown).
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Example 12
Expression of Omi/HtrA2 Protein in Proximal
Tubule (MPT) Cells
50

To investigate the expression of Omi/HtrA2 protein in
proximal tubule (MPT) cells, MPT cells were isolated from
the kidneys of 4-5 week old mice as described in the Example
1. Confocal microscope images of two representative populations of MPT cells were stained with anti-Omi (red) and
anti-gp330 (green). Mouse proximal tubular cells were grown
for 6 days on microscope cover glass. Adherent cells were
stained using a rabbit anti-Omi and a mouse anti-gp330 at
room temperature for 2 hours. Secondary antibodies used
were: cy3 conjugated anti-rabbit and Oregon-green conjugated anti-mouse. Images were obtained using a LSM510
confocal laser scanning microscope (Zeiss). MPT cells were
stained with anti-Omi/HtrA2 (Al and Bl). The same MPT
cells were stained with anti-gp330 antibodies (green) (A2 and
B2). Merged images of 1 and 2 (A3 and B3). Nomarsky
images (A4 and B4). The results show that all MPT cells
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The subcellular localization of Omi/HtrA2 in normal and
apoptotic MPT cells was investigated by as described in
Example 1. Confocal microscope images of normal or apoptotic MPT cells stained with anti-Omi (red) and MitoTracker
(green) (data not shown). Apoptosis was induced using 2 µM
Antimycin for 1 hour. Omi antibody staining was done as
described in Example 1.50 nM of Mi to Tracker dye was added
for 20 minutes. MPT cells stained with anti-Omi/HtrA2 (red)
(1). The same MPT cells stained with anti-gp330 antibodies
(green) (2) and Nomarsky images of the MPT cells were also
produced. The results show that Omi/HtrA2 protein and distinct punctate perinuclear staining in normal MPT cells and
co-localizes with mitochondrial staining. After induction of
apoptosis MPT cells show more intense Omi/HtrA2 staining
that is more diffuse and extends throughout the cell.

Example 14

The Protein Level of Omi/HtrA2 Increases in MPT
Cells Induced with Various Apoptotic Stimuli

To investigate the protein level of Omi/HtrA2, MPT cells
were isolated and exposed to different concentrations of cisplatin for 48 hours, or they were treated with 2 µM antimycin
for different time periods. Approximately 5 µg protein of total
cell extract was resolved by SDS-PAGE, PAGE, transferred to
a PVD F membrane and pro bed using the anti-Omi antibodies
as described in Example 1.
Western blot analysis showed up-regulation of Omi/HtrA2
protein following inductionofapoptosis (See FIG. lla ). Both
cisplatin and antimycin treatment induced expression ofOmi/
HtrA2 protein in MPT cells.
A Western blot analysis of Omi/HtrA2 protein in HK-2
(human proximal tubular epithelial cell line) cells after induction of apoptosis using the indicated concentrations ofH 2 0 2
for 18 hours is shown in FIG. llb. The results show that the
basal protein level ofOmi/HtrA2 is higher in HK-2 cells than
in primary MPT cells. In the HK-2 cell line, there is also
substantial increase in the level of the Omi/HtrA2 protein
after induction of apoptosis with H 2 0 2 .
Example 15

60

Ucf-101 Protects MPT Cells from Cisplatin-Induced
Apoptosis
65

This example describes the protective effects of an inhibitorofapoptosis, Ucf-101 oncisplatin-induced apoptosis. Cis-
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platin used at low doses can also induce apoptosis in RTECs
whereas high doses induce necrosis (Lieberthal, et al. (1996)
Am J Physiol, 270, F700-8; and Lau, et al. (1999) Kidney Int,
56, 1295-8). Early animal studies have shown apoptosis to
occur in rat kidney cortexes 12 hours after ischemia/reperfusion (Schumer, et al (1992) Am J Pathol, 140, 831-8). More
studies have described apoptosis to occur in ischemia/reperfusion injury to the kidney (Nakajima, et al. (1996) Am J
Physiol, 271, F846-53; Yin, et al. (1997) J. Biol Chem, 272,
19943-50; Nogae, et al. (1998) J Am Soc Nephrol, 9, 620-31;
and Raafat, et al. (1997) Shock, 8, 186-92). Ucf-101 was
isolated for its ability to inhibit the proteolytic activity of
Omi/HtrA2 in vitro (Cilenti, et al. (2003) J. Biol Chem, 278,
11489-94).
The ability ofucf-101 to passively enter mammalian cells
makes it possible to be used for in vivo studies. It was hypothesized that if Omi/HtrA2 through its proteolytic activity plays
a role in tubular cell death following renal injury, ucf-101
inhibitor will have a protective anti-apoptotic function in the
same system. Previous studies have shown that treatment of
MPT cells with cisplatin caused increased expression of p53,
and this induction of p53 was necessary and essential for
cisplatin-induced apoptosis (Cummings, et al. (2002) J Pharmacol Exp Ther, 302, 8-17; and Xiao, et al. (2003) J Toxicol
Environ Health A, 66, 469-79). Furthermore, a recent report
showed that Omi/HtrA2 expression is directly regulated by
p53 at least in HeLa cells (Jin, et al. (2003) Genes Dev, 17,
359-67). It was therefore hypothesized that Omi/HtrA2 was
involved in the cisplatin-induced apoptosis as a downstream
effector of p53 and ucf-101 was tested as an inhibitor of in
cisplatin-induced apoptosis.
FIG. 12 shows that ucf-101 blocks cisplatin-induced apoptosis in MPT cells. MPT cells were treated with either 20 µM
or 50 µM ucf-101 for 20 minutes. After this time, apoptosis
was induced with different concentrations of cisplatin for 6
hours. Cells were detached, washed with PBS and stained
withannexin Vaccordingto BD Biosciences protocol.Analysis of annexin V positive cells was performed on a FACS
Vantage Flow Cytometer (Becton Dickinson). Results shown
are the average values from three independent experiments.
The data shows that ucf 101 reduces apoptosis in a dosedependent manner in cisplatin induced apoptotic cells.
Collectively, the data shows that Omi/HtrA2 is expressed
in the kidney proximal tubules, an area highly susceptible to
injury and cell death. Furthermore, the protein level of Omi/
HtrA2 dramatically increased after kidney ischemia/reperfusion in MPT cells treated with antimycin or cisplatin as well
as in HK-2 cells treated with H 2 0 2 . Finally, ucf-101, a specific inhibitor of the proteolytic activity ofOmi/HtrA2, protects MPT cells from cisplatin-induced apoptosis. These
results suggest that Omi/HtrA2 plays an important role in
injury/apoptosis that occurs in proximal tubule cells following ischemic or chemical insult.

spliced form (D-Omi) has been isolated by this group, and is
found predominantly in the kidney and to a lesser extent in the
colon and thyroid (Faccio, et al. (2000) Genomics, 68, 343-7).
D-Omi lacks the amino acid sequence encoded by exons 3
and 7 that affects both its catalytic domain as well as the PDZ
domain. The function of D-Omi is not known. Its restricted
tissue-specific expression might suggest a specific role in the
organs where it is found.
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Example 16
The Function ofD-Omi
This example investigates the roles of D-Omi, a kidneyspecific, alternatively spliced form of Omi/HtrA2. Omi/
HtrA2 is expressed ubiquitously but recently an alternatively

65

To investigate the function of exon 3 that encodes part of
the catalytic domain as well as exon 7 that encodes part of the
PDZ domain, a number of chimeric proteins were made. A
schematic diagram of these proteins is shown in FIG. 13. This
list contains Omi/HtrA2 as well as D-Omi/HtrA2, Omi-ll3
that lacks only the sequence encoded by exon 3 and Omi-ll7
that lacks the sequence encoded by exon 7. Furthermore,
several other constructs were made where the catalytic activity ofOmi/HtrA2 was destroyed by an S/A substitution and an
Omi/HtrA2 construct where both the catalytic and PDZ
domains have been replaced with the corresponding domains
ofL56/HtrA2. For example, in Omi-SA, the Ser 306 (s) was
replaced with Ala (A); Omi-L5 6 chimera is a construct where
the N-terminus ofOmi-HtrA2 including theAVPS motif was
fused to L56 protein form the amino acid 156-480. Omi-L56S/A is a mutated form ofomi-L56, where the Ser 328 has been
mutated to Ala. All of these constructs were cloned into
EGFP-Nl vector. the conserved amino-terminal mitochondria targeting sequence (MTS) is shown, this is followed by
the catalytic domain (which includes the AVPS motif), the
catalytic domain if followed by the PDZ domain. All of these
proteins were expressed as fusions with the green fluorescent
protein (GFP). After transfection into manimalian cells, their
localization, processing and ability to induce apoptosis was
monitored.
FIG.14 shows the expression and processing of the various
GFP-fusion proteins. Equal amounts of whole-cell lysates
obtained 24 hours post-transfection were subjected to SDSPAGE followed by immunoblotting using anti-GFP antibodies. Lanes 1-7, cell lysates prepared from HeLa cells transfected with the corresponding construct: Omi-GFP, Omi-S/
A-GFP, Omi-L56-GFP, Omi-L56-S/A-GFP, Omi-ll7-GFP,
Omi-ll3-GFP, and D-Omi-GFP
FIG. 15 shows the results from an apoptotic assay of various GFP-fusion proteins. 293T cells were transfected using
the same constructs shown in FIG. 13. 48 hours later, transfected cells were detached and stained with PE-conjugated
annexin V. The percentage of GFP positive cells that were also
annexin V positive is shown. The number represents the average of four independent experiments.
This data shows that D-Omi, due to its inability to function
as a protease, is not processed to the mature form of the
protein. This causes the amino terminal part (aa 1-133) that is
usually removed in the mature Omi/HtrA2 protein to remain
attached on D-Omi. As a result, D-Omi is unable to induce
apoptosis in a caspase-dependent manner since it can not
expose the AVPS internal sequence motif necessary for binding to the inhibitor of apoptosis proteins (IAPs ). Furthermore,
since it is an inactive protease, it cannot induce apoptosis in a
caspase-independent pathway. The results showed that
D-Omi still retains some residual activity and it is able to
induce apoptosis in 15% oftransfected 293T cells, which is
approximately half the apoptotic potential of mature Omi/
HtrA2. The function ofD-Omi is not known; it could act as a
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dominant negative, blocking the activity of Omi/HtrA2, or it
could induce apoptosis in a new, independent mechanism.

There are seven identified 14-3-3 isoforms in mammals
and these are highly conserved through evolution from the
yeast to mammals. 14-3-3 proteins are phosphoserine-binding proteins involved in cellular proliferation, checkpoint
control and apoptosis (Aitken, et al. (1995) supra). The mode
ofaction of14-3-3 proteins is not due to any intrinsic activity.
Instead, it relies entirely on the ability of 14-3-3 proteins to
bind specific targets and modify their activity. For instance,
14-3-3 binding to BAD competes with Bc12 binding, relieving Bc12 for its antiapoptotic function (Datta, et al. (2000)
Mal Cell, 6, 41-51). 14-3-3 proteins canalsomodifythetarget
protein localization (Muslin, et al. (2000) Cell Signal, 12,
703-9), bridge two proteins together (Luo, et al. (1996)
Nature, 383, 181-5), alter the catalytic activity of the target
protein, or they can protect the target protein from modifications such as dephosphorylation (Chiang, et al. (2001) Blood,
97, 1289-97). Approximately 70 target polypeptides for
14-3-3 proteins have been identified so far (Tzivion, et al.
(2000) J. Biol Chem, 275, 29772-8). If 14-3-3 proteins are
indeed physiological substrates for Omi/HtrA2, it will help to
explain how Omi/HtrA2 causes caspase-independent cell
death. It has been reported that when the 14-3-35 protein (one
of the seven 14-3-3 isoforms) was disrupted in a human
colorectal cancer cell line, cells arrested in the G2 phase and
ultimately perished by non-apoptotic cell death (Chan, et al.
(1999) Nature, 401, 616-20).
Annexin V is a vascular anticoagulant protein that is normally present on the cytosolic site of the plasma membrane
(Tait, et al. (l988)Biochemistry, 27, 6268-76; andReutelingsperger, et al. (1988) Eur J. Biochem, 173, 171-8). Annexin V
is a member of the calcium dependent phospholipid binding
annexin/lipocortin protein family. It is composed of 320
amino acid residues folded into a planar cyclical arrangement
of four 70-amino acid repeats (Huber, et al. (1992) Behring
Inst Mitt, 107-25). Most cells and tissues express annexin V
(Kaetzel, et al. (1989) Biochem Biophys Res Commun, 160,
1233-7). Some known activities of annexin V include collagen binding (Pfaffie, et al. (1988) EMBO J, 7, 2335-42),
formation of voltage dependent calcium channels (Rojas, et
al. (1990) J. Biol Chem, 265, 21207-15) and inhibition of
phospholipase A2 (Pepinsky, et al. (1988) J. Biol Chem, 263,
10799-811) and protein kinase C (Schlaepfer, et al. (1992)
Biochemistry, 31, 1886-91). The high affinity of annexin V
for phospholipids has been exploited as a measure of apopto sis in a variety of cell types. Early apoptosis is characterized
by exposure ofphospholipids to the matrix side of the membrane (Fadok, et al. (1992) J Immunol, 148, 2207-16). Fluorescent-labeled annexin V binding to the newly exposed
phospholipids is used to identify and quantitate apoptotic
cells (Koopman, et al. (1994) Blood, 84, 1415-20; and Vermes, et al. (1995) J Immunol Methods, 184, 39-51).
These data show that both 14-3-3 and Annexin V are
cleared by Omi/HtrA2 and are physiological substrates of
Omi/HtrA2.

Example 17
5

Kidney-Specific Substrates for Omi/HtrA2 Protease
This example describes the identification of substrates for
Omi/HtrA2 protease. Omi/HtrA2 is an active serine protease.
This activity is necessary for processing the precursor protein
to its mature form. This processing exposes an internal AVPS
motif at the amino terminus which is used to bind the inhibitor
of apoptosis proteins (IAP) and induce caspase-dependent
cell death. Furthermore, Omi/HtrA2 can induce apoptosis in
a caspase-independent manner that relies entirely on its ability to function as a serine protease in the cytoplasm of cells.
This observation suggests that the presence of specific substrates for Omi/HtrA2 whose destruction and removal is part
of the caspase-independent apoptotic process. Alternatively,
Omi/HtrA2 might activate a precursor pro-apoptotic protein
through limited proteolytic cleavage.
In order to identify substrates for Omi/HtrA2, the latest
technology in proteomics was used. Human kidney extracts
obtained from BioChain Institute, Inc. (Hayward, Calif.).
These extracts were already fractionated into: (a) kidney
membrane associated proteins and (b) kidney cytoplasmic
proteins. About 200 mg of extract was incubated in the presence of bacterially made His-Omi-134-458. As controls, no
enzyme was added nor was the ucf-101 inhibitor used. After
30 min of incubation at 37° C., the reaction was stopped with
an equal amount of SDS-PAGE buffer. Proteins were analyzed by 2-dimensional gel electrophoresis. This service was
done in Kendrick's lab (Madison, Wis.). This lab specializes
in 2D PAGE and provides a service for academia (http://
www.kendricklabs.com/). When the images of the 2D-gels
were compared, two polypeptides (32 kD and 29 kD) in the
human kidney cytoplasmic fraction were specifically cleaved
by His-Omi (results not shown). This cleavage was prevented
by the specific inhibitor ucf-101. It was also not seen when the
enzyme was left out of the reaction. No proteins were cleaved
in the membrane bound fractions. After scaling-up the reaction, the two polypeptide spots were excised and sent to the
Protein Chemistry Core Facility, Howard Hughes Medical
Institute/Columbia University for mass spectrometry
sequencing.
There, the proteins were identified as 14-3-3 protein and
annexin V. 14-3-3 proteins are small acidic proteins with
molecular mass ranging from 27 to 32 kDa with no detectable
catalytic domain or function (Aitken, et al. (1995) Biochem
Soc Trans, 23, 605-11; Dubois, et al. (1997) J Protein Chem,
16, 513-22; Muslin, et al. (2000) Cell Signal, 12, 703-9;
Shaw, (2000), Curr Biol, 10, R400; and Skoulakis, et al.
(1998) Mal Neurobiol, 16, 269-84. 1998).

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 7
<210>
<211>
<212>
<213>
<220>

SEQ ID NO 1
LENGTH, 9
TYPE, PRT
ORGANISM, Homo sapiens
FEATURE,

10

15

20

25

30

35

40

45

50
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-continued
<221>
<222>
<223>
<220>
<221>
<222>
<223>

NAME/KEY, misc_feature
LOCATION, (5) .. (6)
OTHER INFORMATION: Xaa can be any naturally occurring amino acid
FEATURE,
NAME/KEY, misc_feature
LOCATION, (8) .. (9)
OTHER INFORMATION: Xaa can be any naturally occurring amino acid

<400> SEQUENCE, 1
Pro Arg Ala Ala Xaa Xaa Thr Xaa Xaa
5

1

<210>
<211>
<212>
<213>

SEQ ID NO 2
LENGTH, 52
TYPE, DNA
ORGANISM, Murinae gen. sp.

<400> SEQUENCE, 2
tcgaattcgc tgggggagga gacagtactg tctcctcccc cagcgaattt tt

<210>
<211>
<212>
<213>

52

SEQ ID NO 3
LENGTH, 53
TYPE, DNA
ORGANISM, Murinae gen. sp.

<400> SEQUENCE, 3
taagcgaccc cctcctctgt catgacagag gagggggtcg cttaaaaatc tag

<210>
<211>
<212>
<213>

53

SEQ ID NO 4
LENGTH, 18
TYPE, DNA
ORGANISM, Murinae gen. sp.

<400> SEQUENCE, 4
gcggggcggg gtgcaaac

<210>
<211>
<212>
<213>

18

SEQ ID NO 5
LENGTH, 17
TYPE, DNA
ORGANISM, Murinae gen. sp.

<400> SEQUENCE, 5
gacagccagc accgtgg

<210>
<211>
<212>
<213>

17

SEQ ID NO 6
LENGTH, 17
TYPE, DNA
ORGANISM, Murinae gen. sp.

<400> SEQUENCE,
ttcgttgccg gtccaca

<210>
<211>
<212>
<213>

17

SEQ ID NO 7
LENGTH, 18
TYPE, DNA
ORGANISM, Murinae gen. sp.

<400> SEQUENCE, 7
accagcgcag cgatatcg

18
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What is claimed is:
1. A method of inhibiting Omi/HtrA2 activity, from about
20% to about 90% comprising:
contacting a cell having Omi/HtrA2 activity with an apoptosis inhibiting compound; and
monitoring the inhibition of Omi/HtrA2 activity, wherein
the apoptosis inhibiting compound is selected from the
group consisting of:
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0
60
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where R 1 is selected from the group consisting of a chloride,
nitro group, a carboxy group, a hydroxide, an aliphatic group,
an aromatic group, an acyl group, an alkoxy group, an alkylene group, an alkenylene group, an alkynylene group, a
hydroxycarbonylalkyl group, an anhydride, an amide, an
amine, and a heterocyclic aromatic group, and where R 2 is a
methoxy group.
2. The method of claim 1, wherein the step of contacting
the cell comprises contacting the cell in vivo.
3. The method of claim 1, wherein the step of contacting
the cell comprises contacting the cell in vitro.
4. The method of claim 1, wherein the apoptosis inhibiting
compound is formula I, wherein R 1 is a nitro group (ucf-101 ).
5. The method of claim 1, wherein the apoptosis inhibiting
compound is formula II, wherein R 1 is a chloride and R 2 is a
methoxy group (ucf-102).
6. The method of claim 1, wherein the apoptosis inhibiting
compound is formula III, wherein R 1 is C0 2 H (ucf-103).
7. The method of claim 1, wherein the apoptosis inhibiting
compound is formula IV, wherein R 1 is a nitro group (ucf104).
8. The method of claim 1, wherein the step of monitoring
Omi/HtrA2 activity comprises monitoring a change in fluorescene of an Omi/HtrA2 substrate coupled to a fluorescent
marker.
9. The method of claim 1, wherein the step of monitoring
the inhibition of Omi/HtrA2 activity further comprises monitoring apoptosis of the cell.
10. The method of claim 8, wherein the fluorescent marker
is selected from the group consisting of fluorescein isothiocyanate (FITC), cyanine dye-5 (CYS), cyanine dye-3 (Cy3),
cyanine dye-7 (Cy7), allophycocyanin (APC), tetramethyl
rhodamine isothiocyanate (TRITC), and phycoerythrin (PE).
11. A method of inhibiting Omi/HtrA2 activity, comprising:
contacting a cell having Omi/HtrA2 activity with an apoptosis inhibiting compound; and
monitoring the inhibition of Omi/HtrA2 activity,
wherein the apoptosis inhibiting compound is selected from
the group consisting ofUcf-101 Ucf-102, Ucf-103 and Ucf104.
12. A method for inhibiting caspase-independent apoptosis
in a cell comprising:
contacting a cell having Omi/HtrA2 activity with at least
one apoptosis inhibiting compound selected from the
group consisting ofUcf-101 Ucf-102, Ucf-103 and Ucf104, such that the apoptosis inhibiting compound interacts with Omi/HtrA2 to inhibit the activity of Omi/
HtrA2, wherein the inhibition of Omi/HtrA2 activity
reduces apoptosis in the cell; and monitoring the inhibition of apoptosis.
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